Stockwinners Market Radar for March 13, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

21:28 EDT Faraday Future confirms no exposure to Silicon Valley Bank shutdown - Faraday Future states it is "aware of the current news and reports surrounding Silicon Valley Bank's liquidity concerns. The Company does not have any cash or cash equivalents on deposit at Silicon Valley Bank and does not have any other direct relationship with Silicon Valley Bank. Furthermore, the Company has discussed issues surrounding Silicon Valley Bank with its committed funding partners and they do not expect such issues to impact the Company's committed funding." The company also confirms that it has "received its dealer license from the State of California for its U.S. operations and expects to go to market using a unique direct sales model as previously disclosed on May 18, 2022."

20:21 EDT Cathie Wood's ARK Investment bought 26.7K shares of Tesla today

20:20 EDT Cathie Wood's ARK Investment bought 119.4K shares of Block today

19:34 EDT Astellas Pharma's ph3 study of XTANDI in China meets primary endpoint - Astellas Pharma "announced positive topline results from the Phase 3 China ARCHES study of XTANDI plus androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer versus placebo plus ADT. The study met its primary endpoint, demonstrating a statistically significant improvement in time to prostate-specific antigen progression, defined as a greater than or equal to 25% increase and an absolute increase of greater than or equal to 2 microgram/L above the nadir, which is confirmed by a second consecutive value at least 3 weeks later. At the topline analysis, the safety of XTANDI plus ADT was broadly consistent with the known safety profile for the medication."

19:22 EDT Evertec CEO sells $1.43M in common stock - In a regulatory filing, Evertec disclosed that its CEO Morgan Schuessler sold 40.2K shares of common stock on March 9th in a total transaction size of $1.43M.

18:53 EDT Reunion Neuroscience files lawsuit against Mindset Pharma - Reunion Neuroscience has filed a lawsuit Monday against Mindset Pharma Inc. in the United States District Court for the District of New Jersey, alleging that Mindset knowingly copied Reunion's RE104 compound and misleadingly presented that exact composition to the Patent Office as Mindset's invention while applying for U.S. Patent No. 11,591,353. Reunion thus seeks to add the original and sole inventor of Reunion's RE104 - Dr. Nathan Bryson, Reunion's Chief Scientific Officer - as an inventor of the '353 Patent. Reunion additionally asserts claims for, among others, co-ownership of the '353 Patent, inequitable conduct in the prosecution of the '353 Patent, and breach of contract.

18:10 EDT Momentive Global trading resumes

17:57 EDT Momentive to be acquired by Symphony Technology Group for $1.5B in cash - Momentive announced it has entered into a definitive agreement to be acquired by a consortium led by Symphony Technology Group in an all-cash transaction that values Momentive at approximately $1.5B. Under the terms of the agreement, Momentive shareholders will receive $9.46 per share, representing a premium of approximately 28% to the volume weighted average closing price of Momentive stock for the 10 trading days ending on March 13, 2023, and a 46% premium to the company's closing stock price on the day prior to media rumors regarding a potential sale on October 19, 2022. The transaction, which was approved unanimously by the Momentive Board of Directors, is expected to close in the second or third quarter of 2023, subject to customary closing conditions, including approval by Momentive shareholders and the receipt of required regulatory approvals. The transaction is not subject to a financing condition. Upon completion of the transaction, Momentive's common stock will no longer be listed on any public market. The company will continue to operate under the Momentive name and Momentive and SurveyMonkey brands.

17:46 EDT Nurix Therapeutics cash balance at Silicon Valley Bank was less than 1% - In a regulatory filing, the company states: "On March 10, 2023, Silicon Valley Bank was closed by the California Department of Financial Protection and Innovation and the Federal Deposit Insurance Corporation was appointed as receiver. On March 12, 2023, the U.S. Department of the Treasury, Federal Reserve Board, and FDIC released a joint statement announcing that the FDIC will complete its resolution of SVB in a manner that fully protects all depositors at SVB and that depositors will have access to all of their money starting March 13, 2023. Nurix Therapeutics maintains an operating account at SVB with a cash balance of less than 1% of the Company's total cash, cash equivalents and marketable securities. The remainder of the Company's cash, cash equivalents, and marketable securities is held at other large, global financial institutions. In light of the foregoing, the Company believes that its funds currently held at SVB will be fully available if and when needed and that, given its otherwise limited direct exposure to SVB, its exposure to loss as a result of SVB's receivership is immaterial."

17:38 EDT Meta Platforms 'winding down' digital collectibles or NFTs - The head of Commerce and Financial Technologies at Meta, Stephane Kasriel, tweeted: "Some product news: across the company, we're looking closely at what we prioritize to increase our focus. We're winding down digital collectibles or NFTs, for now to focus on other ways to support creators, people, and businesses. Let me be clear: creating opportunities for creators and businesses to connect with their fans and monetize remains a priority, and we're going to focus on areas where we can make impact at scale, such as messaging and monetization opps for Reels. And we'll continue investing in fintech tools that people and businesses will need for the future. We're streamlining payments w/ Meta Pay, making checkout & payouts easier, and investing in messaging payments across Meta." Reference Link

17:32 EDT Altus Power confirms no exposure to SVB, Signature Bank or First Republic Bank - The company states: " Altus Powe (AMPS), the premier independent developer, owner and operator of commercial-scale solar facilities, updated stakeholders that it has no exposure to Silicon Valley Bank (SIVB), Signature Bank (SBNY) or First Republic Bank (FRC) or their affiliates. Altus Power holds its cash and equivalents, and marketable securities at other institutions and the Company is not party to any financing agreement with any of these institutions or their affiliates. As recently disclosed, Altus Power's undrawn financing commitments under its revolving credit facility are provided by a diverse syndicate of large financial institutions including Citibank, Bank of America, JP Morgan Chase Bank, KeyBank National Association and Truist Securities, Inc. The Company has fully funded financing facilities with KeyBank and Huntington National Bank associated with the DESRI acquisition. Blackstone Structured Finance Group has provided the Company with investment grade term loan facilities, which are funded by Blackstone on behalf of its insurance franchise. Altus Power will continue to monitor the broader financial landscape, including the impacts on any third parties with which the Company conducts business, but currently anticipates uninterrupted access to capital to fund its ongoing operations and capital expenditures."

17:29 EDT Opendoor Technologies says held less than 1% of total cash at SVB Financial - In a regulatory filing, the company states: "In light of recent Federal Deposit Insurance Corporation action and market volatility, we wanted to provide insight into our liquidity and capital resources. Opendoor Technologies (OPEN) held less than 1% of our total cash, cash equivalents and restricted cash at Silicon Valley Bank (SIVB) and our critical business operations were not run from SVB accounts. As of March 13, 2023, approximately 98% of our total cash, cash equivalents and restricted cash is held at the nation's four largest banks."

17:17 EDT Bunge to replace Signature Bank in S&P 500 at open on 3/15 - The FDIC announced that it has taken Signature Bank into FDIC Receivership and therefore Signature Bank is no longer eligible for inclusion.

17:03 EDT ODP Corporation announces stock repurchase from HG Vora - The ODP Corporation announced that it has agreed to repurchase 2M shares of common stock of the company from HG Vora Special Opportunities Master Fund, at a price per share equal to $44.55, for a total purchase price of approximately $89.1M. The company anticipates borrowing under its asset-based lending facility to finance the transaction. ODP's Board of Directors authorized the transaction as part of ODP's existing $1B share buy-back plan that was previously announced on November 2, 2022. Prior to the transaction, HG Vora owned 5M shares, or approximately 12.4% of the company's outstanding common stock based on the previously disclosed outstanding shares of common stock of the company as of February 22. Following the transaction, HG Vora will own 3M shares, or approximately 7.9% of the company's outstanding shares of common stock, based on the outstanding shares as of February 22, and maintain representation on ODP's Board of Directors.

16:52 EDT International Money Express CEO sells $3.7M in common stock - In a regulatory filing, International Money Express disclosed that its CEO Robert Lisy sold 150K shares of common stock on March 10th in a total transaction size of $3.7M.

16:50 EDT QCR Holdings VP Gipple buys $200K in company shares - QCR Holdings VP Todd Gipple disclosed in a regulatory filing that he had purchased 4,313 shares of company stock at $46.28 per share on March 10 for a total transaction amount of $199,606.

16:37 EDT Acri Capital Acquisition extends deadline for initial business combination - Acri Capital Acquisition announced that, in order to extend the date by which the Company must complete its initial business combination from March 14 to April 14 for each public share that is not redeemed by the Company's stockholders in connection with such Extension , Acri Capital Sponsor , the sponsor of the Company, has deposited into its trust account an aggregate of $227,730.87, representing $0.0625 per public share of the Company. Pursuant to the Company's current Charter, the Company may extend on monthly basis from March 14, 2023, until December 14, 2023 or such an earlier date as may be determined by its board to complete a business combination by depositing the Monthly Extension Payment for each month into the Trust Account.

16:35 EDT United Airlines falls 7% to $45.35 after guiding Q1 EPS below estimates

16:33 EDT Zynerba confirms does not hold cash deposits, securities at Silicon Valley Bank - Zynerba Pharmaceuticals issued a statement confirming that it does not hold cash deposits or securities at Silicon Valley Bank.

16:31 EDT FMC Corporation: Chief sustainability officer Dr. Karen Totland retires - FMC Corporation has announced the retirement of Dr. Karen Totland, vice president and chief sustainability officer, following a nearly 30-year career in the specialty chemical industry. Julie DiNatale, director of Truterra Sustainability Partnerships, a division of Land O'Lakes, will succeed Totland as vice president and CSO on July 1. DiNatale will report to Mark Douglas, president and CEO, and will join the company's Operating Committee.

16:30 EDT ContextLogic says less than 5% of cash was held at Silicon Valley Bank - ContextLogic (WISH) issued the following statement in response to the recent collapse of Silicon Valley Bank (SIVB). "ContextLogic maintains its cash and short-term investments with a diverse group of large national financial institutions," said Vivian Liu, CFO and COO of Wish. "As of December 31, 2022, less than 5% of the Company's $719 million of cash, cash equivalents and marketable securities was held at Silicon Valley Bank (SVB). Therefore, we do not expect the SVB situation to materially impact the Company's overall liquidity position or its day to day operations."

16:29 EDT Americold announces $3.9M strategic investment in RSA Cold Chain in Dubai - Americold Realty Trust announced a strategic investment into RSA Cold Chain in Dubai. At close, Americold's investment is $3.9M for the Company's share, 49%, of RSA Cold Chain equity. This partnership will provide a scalable, investable operating platform for market entry and expansion in the Middle East and India. RSA Cold Chain is an established cold storage operator in Dubai that began operations in 2017 and is a subsidiary of the parent company RSA Global. Americold will take a minority ownership position in RSA Cold Chain with immediate plans to expand locally, connect RSA to its global network, and pursue strategic development opportunities in the Middle East and surrounding markets. RSA Cold Chain is led by Abhishek Shah, who brings significant value to Americold as a strategic partner to establish a new presence in this critical global market. Abhishek Shah, RSA Cold Chain's Co-Founder & CEO, commented, "We are absolutely thrilled to partner with Americold, a global player that can connect the world's food production markets to our region with a seamless service at origin and destination. We are excited to create a regional brand across our markets that our customers can trust."

16:27 EDT Crispr Therapeutics CFO Brendan Smith to depart, Raju Prasad to succeed - Crispr Therapeutics announced the hiring and appointment of Raju Prasad as CFO, effective March 14. He joins the company from William Blair & Company, where he served as a partner and senior equity research analyst covering cell therapy, gene therapy, and gene editing companies. Prasad succeeds Brendan Smith, who is leaving the company to pursue external opportunities.

16:21 EDT Newell Brands CFO buys $990.8K in common stock - In a regulatory filing, Newell Brands disclosed that its CFO Mark Erceg bought 77K shares of common stock on March 9th in a total transaction size of $990.8K.

16:14 EDT BlueRiver Acquisition Corp trading halted, news pending

16:06 EDT DocGo awarded $180M in new business in U.S. and U.K. - The company states: "DocGo announced that since the start of 2023 DocGo has had multiple new single and multi-year revenue contract wins as well as contract expansions valued at over $180 million over the next three years. These include new customer relationships with a premier not-for-profit health system serving Philadelphia and its western suburbs, a leading hospital network on Long Island, multiple federally funded hospitals, a Primary Care Network in South West London, UK, as well as expanded relationships with Philadelphia's largest hospital network, and with the largest municipal health care system in the nation. With these contracts, DocGo will expand mobile health services to include population health programs in New York, paramedic-led home visit services in the UK, the rights to offer remote patient monitoring to patients in Pennsylvania, medical transportation to more than 25 acute-care hospitals, event medical standby and hospital support services. The company expects all related contracts to be fully rolled out by the end of Q3 2023."

16:03 EDT Aspen Group to voluntarily delist common stock from Nasdaq - Aspen Group announced that it has given formal notice to the Nasdaq Stock Market of its intention to voluntarily delist its common stock from the Nasdaq Capital Market and to deregister its common stock under Section 12(b) of the Securities Exchange Act of 1934 .The Company currently anticipates that it will file with the Securities and Exchange Commission a Form 25, Notification of Removal of Listing and/or Registration Under Section 12(b) the Exchange Act, relating to the delisting and deregistration on or about March 23, 2023, with the delisting of its common stock taking effect no earlier than ten days thereafter. As a result, the Company expects that the last trading day of its common stock on the Nasdaq Capital Market will be on or about March 31. Further, on or about April 30 , the Company intends to file a Form 15 with the SEC to suspend the Company's reporting obligations under Section 15(d) of the Exchange Act.

15:58 EDT Archer says SVB receivership has no impact on business, operations - Archer Aviation (ACHR) said it currently maintains only a small amount of cash with SVB (SIVB), in the single digit millions of U.S. dollars, representing less than 2% of the company's total cash, cash equivalents and short-term investments. Accordingly, the SVB receivership is not expected to have any impact on its business or operations.

15:39 EDT Bank of Hawaii says deposits 'well-diversified by industry and depositor type' - Bank of Hawai'i Corporation, parent company of Bank of Hawai'i, provided an operational overview in "light of recent industry events and market volatility," stating in a regulatory filing: "Deposits are well-diversified by industry and depositor type - the average consumer balance is $18,000; the average commercial balance is $134,000. We have ample liquidity and our regulatory capital ratios remain strong." Reference Link

15:35 EDT Amesite confirms no exposure to Silicon Valley Bank SVB - Amesite (AMST) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SIVB), and has no current or prior business relationship with SVB.

14:47 EDT Microchip reaches milestone in $800M initiative to triple semi output in Oregon - Microchip Technology has reached a milestone in its multi-year, $800M initiative aiming to triple production capacity at its Gresham, Oregon manufacturing facility. Celebrating close to the halfway mark in a major workforce expansion and capital equipment investment, the efforts are part of Microchip's larger initiative to ramp up overall production in the U.S. as demand continues to grow for semiconductor products across a broad range of industries. "We want to recognize the Microchip Gresham team for their dedication and ongoing hard work on this expansion and thank the state of Oregon and its elected officials for the incentives they have approved in support of its completion," said Ganesh Moorthy, President and CEO of Microchip Technology. "Our steady growth demonstrates the vital role of semiconductors and the importance of the CHIPS & Science Act for providing the economic support required to help level the global playing field for U.S. companies." Working with the Business Oregon state economic development agency, the City of Gresham and Multnomah County, Microchip has been approved to receive state and local incentives of approximately $42.4 million for the expansion.

14:02 EDT Nasdaq halts Signature Bank trading - The Nasdaq Stock Market (NDAQ) announced that trading was halted on March 13, 2023 in Signature Bank (SBNY) at 04:00:01 Eastern Time for "additional information requested" from the company at a last sale price of $70.00 for SBNY and $11.90 for SBNYP.

13:46 EDT RocketFuel Blockchain says it has no exposure to Silvergate or SVB - RocketFuel Blockchain (RKFL) confirmed that it has no relationship with, or exposure to, Silicon Valley Bank (SIVB) or Silvergate Bank (SI). "We have accounts with several large, well established banks around the world and none of them are impacted by the recent turmoil caused by the failures of Silicon Valley Bank or Silvergate Bank," stated Peter Jensen, RocketFuel's CEO. "Rocketfuel is a payments infrastructure company and not an exchange. We do not own or hold cryptocurrencies, and therefore have no exposure to any volatility of cryptocurrencies. When payments are received from shoppers, they are instantaneously exchanged to FIAT currencies (primarily USD and EUR) and transferred into our merchants' bank accounts."

13:34 EDT American Electric Power appoints Kate Sturgess as controller, CAO - American Electric Power has named Kate Sturgess senior vice president, controller and chief accounting officer effective May 9. In this role, she will be responsible for all aspects of accounting, financial reporting and regulatory accounting services. Sturgess will report to Ann Kelly, executive vice president and CFO. She will succeed Joseph Buonaiuto, senior vice president, controller and chief accounting officer, who will retire July 1 after more than 21 years with the company. Sturgess most recently was vice president, Controller for Edison International and its subsidiary Southern California Edison.

13:21 EDT Genelux Corp trading resumes

13:12 EDT PagSeguro Digital says no exposure to Silicon Valley Bank - PagSeguro Digital, or PagBank PagSeguro (PAGS) said in a regulatory filing that informs its that "neither the Company nor any of its subsidiaries have any exposure to Silicon Valley Bank" (SIVB).

13:06 EDT Genelux Corp trading halted, volatility trading pause

12:52 EDT 9 Meters Biopharma confirms it doesn't hold deposits, securities at SVB - 9 Meters Biopharma (NMTR) confirmed in a regulatory filing that it does not hold any deposits or securities or maintain any accounts at Silicon Valley Bank (SIVB).

12:33 EDT Q2 Holdings says less than $5,000 in cash held at SVB, no deposits at Signature - In a regulatory filing, Q2 Holdings (QTWO) informs its investors that Q2 maintains less than $5,000 in cash deposits at Silicon Valley Bank (SIVB) and holds no securities at Silicon Valley Bank. Q2 maintains no cash deposits and holds no securities at Signature Bank (SBNY). "While, Silicon Valley Bank is a customer of Q2, total revenue from Silicon Valley Bank recognized for the year ended December 31, 2022 represented less than one half of one percent of Q2's total revenue for the year. Signature Bank is not a Q2 customer. Q2 is actively monitoring the financial services and broader markets and assessing the impacts that events may have on Q2's customers, third-party relationships and operations. Q2 has a diversified customer base with no individual customer representing more than 4% of total revenue, and Q2's top 20 customers collectively accounting for less than 25% of its total revenue, each for the year ended December 31, 2022," the company added in its filings.

12:00 EDT AvePoint says no deposits, other direct investments held at SVB - In a regulatory filing, AvePoint (AVPT) stated that the company is aware that the Federal Deposit Insurance Corp. has taken control of Silicon Valley Bank (SIVB). "The company does not hold any deposits at SVB or have any other direct investments at SVB," AvePoint said.

12:00 EDT Western Alliance falls -52.8% - Western Alliance is down -52.8%, or -$26.06 to $23.28.

12:00 EDT Direxion Daily Jr Gld Mnrs Bull 3X Shrs rises 14.8% - Direxion Daily Jr Gld Mnrs Bull 3X Shrs is up 14.8%, or $4.40 to $34.10.

12:00 EDT ProShares Bitcoin Strategy ETF rises 21.2% - ProShares Bitcoin Strategy ETF is up 21.2%, or $2.59 to $14.85.

11:43 EDT SuperCom reports no exposure to Silicon Valley Bank, Signature Bank - SuperCom (SPCB) announced that it has no exposure to Silicon Valley Bank (SIVB) and Signature Bank (SBNY). "Neither SuperCom, nor any of its subsidiaries, have any banking relationship with either of these banks," the company stated in a press release.

11:22 EDT Inter&Co says does not have exposure to Silicon Valley Bank - Inter&Co (INTR) informs its shareholders and the market that the company and its subsidiaries do not have any exposure or business relationship with Silicon Valley Bank (SIVB).

11:13 EDT Safeguard says seven ownership interests have banking relationships with SVB - Safeguard Scientifics (SFE) is providing the following summary assessment of the initial impact of Silicon Valley Bank's (SIVB) closing on Friday March 10, 2023 by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver, and the subsequent announcement on March 12, 2023, whereby the FDIC will complete its resolution of Silicon Valley Bank, Santa Clara, California, in a manner that fully protects all depositors. The company said, "Safeguard does not have a banking relationship with Silicon Valley Bank. Seven of Safeguard's ownership interests have banking relationships with Silicon Valley Bank. Those relationships include depository accounts, outstanding loans, and undrawn lines of credit. In addition, one of Safeguard's Other ownership interests, of which Safeguard has an ownership interest of approximately 2%, also has significant depository amounts at Silicon Valley Bank. Following the announcement on March 12, 2023, whereby the FDIC will complete its resolution of the receivership of Silicon Valley Bank, Santa Clara, California, in a manner that fully protects all depositors, we believe that these seven companies will have access to their funds in a manner that will not interfere with their ordinary course operations. If there are any delays with respect to accessing these funds, Safeguard will work with the management teams and other stakeholders to find solutions to any near-term issues. In addition, two companies had an aggregate of $9M of undrawn loan commitments from Silicon Valley Bank. We are working with those management teams to develop alternative and/or additional long-term financing solutions."

11:00 EDT ConocoPhillips 'welcomes' record of decision on Willow project - ConocoPhillips said in a statement that it "welcomes" the Department of the Interior's Record of Decision on the Willow project, adopting the three core pads detailed in the Bureau of Land Management preferred Alternative E. ConocoPhillips Alaska completed extensive preparations with key contractors and expects to immediately initiate gravel road construction activities, it said, adding that the company continues to review the ROD and will advance internal approval processes towards a Final Investment Decision. "This was the right decision for Alaska and our nation," said Ryan Lance, ConocoPhillips chairman and chief executive officer. "Willow fits within the Biden Administration's priorities on environmental and social justice, facilitating the energy transition and enhancing our energy security, all while creating good union jobs and providing benefits to Alaska Native communities."

10:46 EDT LiveOne's LiveZone Daily approved as official Discover Partner on Snapchat - LiveOne (LVO) announced that LiveZone Daily, LiveOne's daily music and pop-culture news show, has joined Snapchat (SNAP) as a Discover Partner in order to expand its audience and reach to millions of fans. Earlier this month, LiveZone Daily kicked off its daily music news bites on Snapchat Discover to Snapchat's 363 million daily active users, the company said. Launched on TikTok in 2022, LiveZone Daily has skyrocketed to well over 20 million views and over 1.5 million engagements in the last 60 days, with multiple videos garnering over 2-9 million views, it added.

10:41 EDT JX Luxventure forms second partnership with China Southern Airline - JX Luxventure (JXJT) announced that on March 12, 2023, it has entered into a Memorandum of Understanding with China Southern Air Cross-Border E-Commerce (ZNHYY) in connection with JXJT using the distribution channels of China Southern Airline for selling imported pet foods.

10:33 EDT Icahn: Nominees to bring 'badly needed dose of sanity' to Illumina's boardroom

10:32 EDT Carl Icahn issues open letter to Illumina shareholders - Carl Icahn issued an open letter to Illumina (ILMN) shareholders. The letter says in part: "We know from talking with many of you that there is extreme displeasure among the owners of Illumina. $50 billion of value has been wiped from the company's market capitalization since August 2021. This value destruction is a direct result of a series of ill-advised (and frankly inexplicable) actions taken by the board of directors of our company in connection with the acquisition of GRAIL, Inc. To paraphrase William Shakespeare's Hamlet, something is rotten in the state of Illumina.... llumina's share price performance, and the $50 billion of value destruction that has occurred since the GRAIL deal was closed, clearly shows that shareholders have lost faith in Illumina's management team and board of directors. Yet these individuals suffer no consequences or remorse. The members of Illumina's management team and board of directors collectively own less than 0.1% of the company's stock yet they feel entitled to take these reckless actions with our money. For the past few weeks, we have been working privately to try to find a way to help Illumina and our fellow shareholders. Unfortunately, our efforts have failed to gain traction with the Illumina board and we have therefore determined to launch a proxy contest to attempt to gain board representation due to our fear that Illumina's directors will pursue GRAIL until the end of time without regard to the amount of value destruction they leave in their wake. We are today announcing our intention to nominate three highly qualified individuals to Illumina's board of directors at the upcoming annual meeting of shareholders, who will tirelessly pursue justice for ALL shareholders. We believe our three nominees will bring a badly needed dose of sanity to Illumina's boardroom." Icahn is nominating Vincent Intrieri, Jesse Lynn, the general counsel of Icahn Enterprises (IEP), and Andrew Teno, a portfolio manager at Icahn Capital.

10:25 EDT KeyCorp trading halted, volatility trading pause

10:22 EDT Metropolitan Bank Holding Corp trading resumes

10:15 EDT Summit Healthcare Acquisition Corp trading halted, volatility trading pause

10:05 EDT MAIA Biotechnology reports no exposure to Silicon Valley Bank - MAIA Biotechnology(MAIA) announced the Company has no exposure to Silicon Valley Bank (SIVB). The Company is aware that the Federal Deposit Insurance Corp. has taken control of SVB due to liquidity concerns. The Company confirms it does not hold any deposits or investments at SVB, as well as at Silvergate Bank (SI), or Signature Bank (SBNY). MAIA's cash is managed across a top-tier financial institution.

10:03 EDT Omniq Corp trading resumes

10:00 EDT First Republic falls -66.9% - First Republic is down -66.9%, or -$54.68 to $27.08.

10:00 EDT Direxion Daily Jr Gld Mnrs Bull 3X Shrs rises 13.3% - Direxion Daily Jr Gld Mnrs Bull 3X Shrs is up 13.3%, or $3.95 to $33.65.

10:00 EDT ZIM Integrated rises 17.4% - ZIM Integrated is up 17.4%, or $3.40 to $22.97.

09:55 EDT Macatawa Bank trading resumes

09:47 EDT Genie Energy trading resumes

09:47 EDT First Republic falls -65.1% - First Republic is down -65.1%, or -$53.20 to $28.56.

09:47 EDT Direxion Financial Bear 3x rises 12.4% - Direxion Financial Bear 3x is up 12.4%, or $2.68 to $24.22.

09:47 EDT ZIM Integrated rises 12.6% - ZIM Integrated is up 12.6%, or $2.47 to $22.04.

09:45 EDT Bank of Hawaii trading resumes

09:43 EDT Orchestra Biomed Holdings Inc trading resumes

09:42 EDT Regions Financial trading resumes

09:42 EDT Customers Bancorp trading resumes

09:40 EDT First Horizon trading halted, volatility trading pause

09:40 EDT Zions Bancorp trading resumes

09:39 EDT Bank of Hawaii trading halted, volatility trading pause

09:38 EDT Western Alliance trading resumes

09:38 EDT Orchestra Biomed Holdings Inc trading halted, volatility trading pause

09:36 EDT Regions Financial trading halted, volatility trading pause

09:36 EDT First Republic trading resumes

09:35 EDT Magyar Bancorp trading resumes

09:35 EDT Zions Bancorp trading halted, volatility trading pause

09:33 EDT Mayville Engineering appoints Rachele Lehr as CHRO - Mayville Engineering Company announced the appointment of Rachele Lehr as the Chief Human Resources Officer, effective March 13, 2023. Lehr will report directly to President and CEO Jag Reddy, and will lead the Company's Human Resources strategy, including, talent acquisition, talent development, total rewards, change management, employee engagement, and improvement of the overall HR operating system. Previously, Lehr was the Senior Vice President of Human Resources and Administration for Briggs & Stratton.

09:33 EDT Western Alliance trading halted, volatility trading pause

09:32 EDT East West Bancorp trading halted, volatility trading pause

09:30 EDT PacWest Bancorp trading halted, volatility trading pause

09:30 EDT Magyar Bancorp trading halted, volatility trading pause

09:28 EDT On24 expands capital return program to $125M, announces governance enhancements - ON24 announced that its Board of Directors has authorized an expansion of its recently announced capital return program and a series of governance enhancements. The ON24 Board of Directors has authorized the expansion of its previously announced $100M capital return program by an incremental $25M. Under the expanded $125 million authorization, ON24 will return an additional $25 million to shareholders in the form of a special cash dividend, delivering in the aggregate a $50M special cash dividend payable in the second fiscal quarter of 2023. As previously announced, the Company expects the remaining $75 million of capital return to be effected through a combination of an accelerated share repurchase program and/or open market purchases, to be completed within the next 12 months. Upon completion of the $125 million capital return program, ON24 will have returned $166 million of capital since December 2021. Sharat Sharan, co-founder, CEO and director of ON24, said, "At ON24, our strong balance sheet provides us with the financial flexibility to return this additional capital to our shareholders while continuing to invest in our business. We are pleased to increase the total return, which demonstrates our confidence in ON24's strategy, future growth prospects, and ability to achieve profitability in the near-term as well as underscores our commitment to deliver value to our shareholders." The Company notes that its expanded capital return authorization does not constitute a legal obligation to repurchase shares. The timing, number of shares repurchased, and prices paid for the repurchased shares under this program will be at the discretion of management and will depend on market conditions as well as regulatory limitations.

09:28 EDT Better Choice Company receives expression of interest for Halo pet brand - Better Choice Company announced that it has received expressions of interest for its line of Halo branded pet products. The Company will conduct a strategic alternatives review process to evaluate a sale of the company, merger, divestiture of assets, private placement of securities, or other strategic transactions such as entering into other industries or revenue verticals outside of the pet space. There can be no assurance that this process will result in any such transaction, and the Company does not intend to disclose additional details unless and until it has entered into a specific transaction.

09:25 EDT Primis Financial reports several mid-quarter results - The Company's mobile platform, which augments its core community bank, has opened approximately 10,600 new accounts since the full launch in the fourth quarter of 2022 with total current balances of approximately $921 million and, importantly, this quarter-to-date growth has been without any incremental personnel or system expense. Speaking about the Company's balance sheet strength, Dennis Zember, Jr., President and CEO commented, "Given the turbulence we have witnessed over the past week, I think it is important to update the investment community on certain of our results through the first quarter of 2023. Between concerted efforts to maintain and grow relationships at the core bank and the increasing popularity of the mobile banking platform attracting new customers, we have grown core deposits in the first quarter of 2023 by approximately $908 million through March 9, 2023. This outstanding result has allowed our bank to become 97% core customer funded, with no wholesale borrowings and only $100 million of short-term brokered deposits. As a result, our loan to deposit ratio has dropped to 83% from 108% at December 31, 2022. Currently we have approximately $600 million of cash on our balance sheet compared to only $244 million of investment securities, only 5% of which are classified as held-to-maturity. Lastly, we have approximately $855 million of borrowing capacity from various institutions, including the FHLB." Zember continued, "Our success with these profitable and safe deposit strategies has provided our bank with some of the best liquidity ratios in the industry. Our customer base is diversified by state (in all 50 states), between consumer and commercial and amongst various deposit types. We have zero exposure to crypto-oriented loans or deposits and no exposure to venture capital sponsored businesses. Lastly, our average balances per customer are low, at approximately $44,000 per account and we continue to see meaningful deposit inflows on a daily basis."

09:24 EDT Citius Pharmaceuticals confirms no exposure to Silicon Valley Bank - Citius Pharmaceuticals (CTXR) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SIVB), and has no current or prior business relationship with SVB.

09:23 EDT Vicinity Motor to commence operations in Ferndale, Washington - Vicinity Motor announced the receipt of a Certificate of Occupancy from the City of Ferndale for its newly constructed, state-of-the-art, 100,000 square foot U.S. Manufacturing Campus in Ferndale, Washington. The Certificate of Occupancy certifies that the facility is safe for operations and enables Vicinity to begin operations at site immediately. It is anticipated that vehicle assembly in Ferndale will begin in the first half of 2023.

09:21 EDT Jaguar Health developing AI-powered web portal for Mytesi - Jaguar Health announced that the Company is developing an artificial intelligence-powered web portal for U.S. healthcare professionals to support patient access to Mytesi, the Company's FDA-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

09:20 EDT Aclara Resources awards Penco Module Feasibility Study to P&A - Aclara Resources announced that it has awarded the Penco Module Feasibility Study contract to Pares & Alvarez, a Chilean engineering company with more than 28 years of experience in the design and construction of similar mining and industrial projects, located in both Chile and abroad. The scope of the Penco Feasibility Study contract includes the feasibility engineering for the process plant, mine infrastructure and mine services. Pursuant to the contract, P&A will also be responsible for the preparation of the associated technical report in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects, which is expected to be issued during the first half of 2024.

09:20 EDT Myomo intends to reduce cash burn in 2023 - Cash and cash equivalents as of December 31 were $5.3M. Cash used in operating activities was $2.4M for the fourth quarter of 2022 and $10.2M for the full year 2022. In January 2023, the Company completed an offering of common stock and pre-funded warrants that generated net proceeds of approximately $5.7M. The Company plans to reduce its cash burn in 2023 through a combination of revenue growth and the impact of the aforementioned actions.

09:19 EDT Truist Financial names Hackett as CEO of Truist Securities - Truist Financial announced that John Gregg will retire, and that Tom Hackett has been named chairman and chief executive officer of Truist Securities, Truist's full-service corporate and investment bank, effective March 31. Based in Atlanta, Hackett currently serves as president and chief operating officer of Truist Securities, a position he's held since 2020.

09:18 EDT Disney CHRO Paul Richardson to depart, Sonia Coleman to succeed - Sonia Coleman has been named senior executive VP and chief human resources officer of Disney, effective April 8, it was announced by Robert Iger, CEO. Coleman, who most recently has served as senior VP, human resources for Disney Entertainment and ESPN, succeeds Paul Richardson, who is leaving the company after more than 15 years at Disney. As CHRO, Coleman will report directly to Iger and will be responsible for leading Disney's human resources strategy, global talent acquisition, leadership development, diversity and inclusion, organizational design and cultural development, employee education and development, compensation and benefits, HR operations and technology, and global security.

09:18 EDT SWK Holdings says does not have direct exposure to SVB - In a regulatory filing, SWK Holdings (SWKH) reported that the company is aware that Silicon Valley Bank (SIVB) was closed on March 10 by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. "The company does not have direct exposure to SVB. The company does not hold cash deposits or securities with SVB, and does not otherwise have a business relationship with SVB. In addition, the company is not party to any debt financing arrangement in which SVB is an agent, co-lender, or a participant," SWK Holdings stated.

09:17 EDT Myomo preparing for DME MAC meeting on Medicare Part B payments for MyoPro - "We are preparing for a meeting with the DME MAC medical directors to discuss payment of the MyoPro for Medicare Part B patients and expect to submit our initial Medicare Part B claims as a direct provider before the end of the first quarter." continued Mr. Gudonis. "As we anticipated, CMS issued a public notice in January regarding its intention to propose a new rule that defines the scope of the Medicare Part B benefit for leg, arm, back and neck braces, as well as for newer technology devices. We expect that this new rule will address the request we made in June 2022 to change our benefit category from DME rental to a brace, or orthotic. We don't have any information regarding the timing for the publication of this proposed rule," said the company in an earlier statement.

09:17 EDT ASP Isotopes expects to announce future manufacturing site in next 12 months - ASP Isotopes announced a letter to stockholders from Chairman and CEO Paul Mann. The letter read, in part, "It is now almost 18 months since we founded ASP Isotopes, and I wanted to take this opportunity to provide an update on recent achievements and future goals, share some perspectives on the state of the global industry and, finally, remind everyone of the reasons we entered this industry. The most important news for investors is that our first isotope enrichment facility commenced operations this week -a major milestone in our company's short history....The ASP technology is unique compared to many other methods currently used for isotope enrichment. The plants we can construct using ASP technology are small, modular and extremely flexible. This allows us to construct plants quickly and efficiently with a relatively small amount of capital. The modular nature means that small facilities can be expanded quickly and efficiently as demand grows. The low capital cost should allow us to achieve a very high return on capital. In addition, the ASP technology is capable of enriching light isotopes that cannot be enriched using other centrifugal methods, and we view this as extremely important given the likely future need for low-mass isotopes such as silicon-28, chlorine-37, deuterium and lithium-6. The original investment was underwritten by the founders and founding investors supported just by a single manufacturing plant for a single isotope in Pretoria, South Africa. Obviously, geopolitical events have subsequently unfolded that have increased our opportunity set exponentially. Historically, Russia has been the largest supplier of isotopes to the Western world, and many governments and companies are currently assessing who their suppliers of critical materials are. Based on the number of conversations we are having with many potential customers, it is becoming evident that we will have to expand our production capacity during the 2024-2027 timeframe. During the next 12 months, we expect to announce the location of this future manufacturing site which we expect to benefit from extremely cheap renewable energy. This should allow us to become the lowest-cost producer of any isotope in a geopolitically favored location. Hopefully, you are as excited as we are about the scale and the commercial opportunities ahead, where our technology can deliver unique products to the world."

09:14 EDT Muscle Maker reports top-line revenue over $58M in February - Muscle Maker announced that it has achieved top line revenue of over $58 million for the month of February 2023. This revenue announcement marks the achievement of 4 consecutive months above $50 million for the company and demonstrates continued success of its wholly owned Sadot subsidiary.

09:12 EDT Adtran, Satelles team on STL tech as 'secure and releable' alternatives to GNSS - Adtran and Satelles announced a strategic partnership. The collaboration will enable operators of critical infrastructure to safeguard their timing networks with Satellite Time and Location technology. By integrating Satelles' STL into its Oscilloquartz network synchronization products, Adtran will provide an alternative to Adtran and Satelles partner to deliver Satellite Time and Location systems or a way to augment them with enhanced reliability and security. With the ability to deliver highly precise PNT service, even in GNSS-denied applications, STL offers a vital resource for mobile operators, power utility companies, government, scientific research and more. We're pleased to be working with Adtran's Oscilloquartz division to integrate STL into its portfolio of PTP network timing devices. Together, we're enabling even more customers to benefit from their game-changing aPNT+ technology," said Christina Riley, VP and GM of commercial enterprise solutions at Satelles. "Leveraging LEO signals that are 1,000 times stronger than GNSS, our STL solution is transforming the PNT industry. It's ideal for providing accurate, reliable timing where GNSS can't reach, such as indoor locations. And in settings where it is possible to receive GNSS signals, STL complements it with additional PNT services to improve resiliency. Easy and affordable to install, STL also offers new levels of security for synchronization network infrastructure."

09:08 EDT CareCloud to highlight healthcare consultation services at ViVE - CareCloud announced its medSR division will sponsor and exhibit in booth 2503 at the upcoming ViVE 2023 conference, March 26-29 in Nashville. The ViVE event is an eagerly anticipated annual event that unites experts from around the world to share their ideas and insights for the future. It covers a wide range of topics, from technologies like AI, blockchain, and IoT, to sustainability, diversity, and social responsibility. At booth 2503, attendees will have the opportunity to meet with medSR representatives and explore their exceptional consultation services. As the consulting division of CareCloud, medSR specializes in providing top-notch information technology and operations solutions to organizations seeking to enhance their business operations. Their extensive expertise in revenue cycle management, operations improvement, information technology strategy and support, all within a single firm, makes them a reliable partner for hospitals and businesses looking to streamline their operations. Working hand in hand with their clients, medSR is able to grasp their unique business requirements and develop customized solutions that are both efficient and effective.

09:06 EDT Bill expects to have access to all corporate deposits and cash - Bill (BILL) said that in light of actions yesterday by U.S. regulators it expects that it will have access to substantially all of its corporate deposits and cash held in trust on behalf of its customers at SVB Financial (SIVB). As a result, Bill believes that the SVB closure will have minimal impact on the company's financial position.

09:05 EDT GrowLife partners with Bill Walton - GrowLife announced this morning at the 35th Annual Roth Conference that Bill Walton has joined the Bridgetown Mushroom team. The Basketball Hall of Famer will take an active role in product development and marketing for Bridgetown Mushrooms.

09:05 EDT Micron releases 2022 DEI report - Micron Technology announced the release of its fifth annual diversity, equality and inclusion report titled, "We are Micron," to mark progress and achievements across its six DEI commitments. "These commitments hold Micron accountable to seek greater diversity, drive equal pay and benefits, strengthen our culture of inclusion and be a positive force for all," said Micron President and CEO Sanjay Mehrotra. "Our commitment to DEI extends globally. It is embedded in our business practices and in our investments for the future."

09:04 EDT Heron says CMS granted pass-through payment status for Aponvie - Heron Therapeutics earlier announced that CMS has approved transitional pass-through status for Aponvie injectable emulsion, which will be established for three years beginning April 1 under C-code C9145. Aponvie was approved by the U.S. Food and Drug Administration for intravenous use in adults for the prevention of postoperative nausea and vomiting, or PONV, and became commercially available on March 6, the company noted. "The granting of pass-through status for Aponvie further facilitates patient access and streamlines billing and reimbursement for all HOPD and ASC settings, which is important with over 70% of the surgery opportunity being conducted in these outpatient settings of care. Receiving pass-through only days after the U.S. launch is encouraging and will provide patients undergoing surgery that are at risk for developing PONV an easy to use, convenient, and highly effective treatment option," said Barry Quart, Pharm.D., Chairman and CEO of Heron.

09:03 EDT Myomo: Adjusted pipeline up 50% as of December 31, company reduced headcount - In 2023, the Company is focusing on working with payers that have reimbursed for MyoPro's in the past, rather than expanding the payer base. The Company's analysis revealed that new payers generated less than 2% of the Company's 2022 revenues, yet consumed significant resources. As a result, the Company reduced its workforce by 12% in January 2023. This and other planned actions are expected to save approximately $2M in 2023. Further, the patient pipeline was re-focused in January on patients with insurance by payers that have reimbursed for the MyoPro in the past. Reflecting this change, the adjusted pipeline was 794 patients as of December 31, an increase of 50%, compared with 528 patients as of December 31, 2021. The Company expects these actions to have a minimal impact on 2023 revenues and to result in a higher authorization rate on a go-forward basis.

09:02 EDT Mr. Cooper says uninsured accounts held in money center, global banks - Mr. Cooper Group made the following disclosures in relation to market events, including the recent closures of national banks: The company's corporate uninsured cash accounts are held in money center and global investment banks; and client funds are held in insured deposit accounts at a mix of money center and regional banks. Separately, the company disclosed that over the course of Q1 it has increased the target hedge ratio on its MSR hedge position to 75% of the net duration risk in its MSR portfolio from 25% at year-end 2022, "with the goal of mitigating the risk to capital and tangible book value in a declining interest rate environment."

09:01 EDT Charles Schwab CEO says company has access to 'significant liquidity' - As part of the company's monthly activity report, Charles Schwab CFO Peter Crawford stated: "Given the events of the past few days, we thought it might be helpful to highlight several factors that enable us to keep delivering for clients and stockholders through a range of market conditions: Schwab's business continues to perform exceptionally well, as our Through Clients' Eyes strategy and 'no trade-offs' positioning resonates with both clients and prospects. February core net new assets totaled $41.7 billion, our 2nd largest February ever (trailing only February 2021, the height of the meme stock craze). Our growth and momentum have continued into March, with daily net new assets averaging nearly $2B per trading day month-to-date. Our financial performance continues to be strong. As we look ahead to our first quarter results, we anticipate year-over-year revenue growth of about 10% relative to Q1 2022, with adjusted1 pre-tax profit margin in the 45-47% range. Client bank sweep cash outflows in February were about $5 billion lower than January and March month-to-date daily average outflows are tracking consistent with February. Importantly, these outflows reflect a continuation of client decisions to reallocate a portion of their cash into higher yielding cash alternatives within Schwab. Based on our ongoing analysis of these trends, we still believe client cash realignment decisions will largely abate during 2023. This activity reflects the collective behavior of our heterogenous client mix of individual retail investors and the advisors who serve them. More than 80% of our total bank deposits fall within the FDIC insurance limits, among the five highest ratios of the top 100 banks in the United States. As a reminder, our deposit base is primarily comprised of transactional cash balances swept to our banks from one of our 34 million brokerage accounts. We have access to significant liquidity, including an estimated $100 billion of cash flow from cash on hand, portfolio-related cash flows, and net new assets we anticipate realizing over the next twelve months. We believe we have upwards of $8 billion in potential retail CD issuances per month, plus over $300 billion of incremental capacity with the Federal Home Loan Bank (FHLB) and other short-term facilities - including the recently announced Bank Term Funding Program (BTFP). Our approach to managing our assets is quite different than traditional banks. So before closing, I wanted to provide some thoughts on recent comments by some pundits regarding unrealized losses within bank held-to-maturity (HTM) portfolios. As a reminder, our banks' loan-to-deposit ratio is approximately 10% and nearly all the loans are over-collateralized by first-lien mortgages or securities. The remainder of our assets are invested in high-quality, liquid securities in either our available-for-sale (AFS) portfolio, working capital at the parent or broker-dealer subsidiaries, or in our HTM portfolio. Focusing attention on unrealized losses within HTM has two logical flaws. First, those securities will mature at par, and given our significant access to other sources of liquidity there is very little chance that we'd need to sell them prior to maturity (as the name implies). Second, by looking at unrealized losses among HTM securities, but not doing the same for traditional banks' loan portfolios, the analysis penalizes firms like Schwab that in fact have a higher quality, more liquid, and more transparent balance sheet." Shares of Charles Schwab are still down 8.3% in pre-market trading following 11.7% decline on Friday and 24% last week overall.

09:00 EDT Arrival finalizing 50% reduction of global workforce in Q1 - Over the last few months the Company has taken decisive steps to significantly reduce its headcount and cash burn. At the same time, it has sharpened its focus on its U.S. product strategy, which will prioritize commencing production of a purpose-built Class 4 XL Delivery Van in the Charlotte factory in late 2024, pending a capital injection this year to fund the program. Recently, the Company was successful in driving organizational efficiencies that will extend the run-rate of existing cash resources into late 2023; it succeeded in arranging up to $350 million of new capital commitments and an agreement to reduce net debt by $121.9 million. Following these actions, the key elements of the business plan are as follows: Lowering the Company's current, targeted cash spend to no more than $35 million/quarter which significantly reduces the size of investment required to fund the business this year.Finalizing a 50% reduction of the Company's global workforce in Q1 that will result in less than 800 employees by the end of March 2023. Building 10 Vans in the Bicester microfactory to further develop the highly automated factory processes and integrate them with the company's autonomous mobile robots. These vans will also be used to accumulate 250,000 kms of public road mileage to validate Arrival's engineering designs and components by the end of 2023. Continued development of the XL Van designed specifically for the U.S. market. This product attracts higher average selling prices, margins and tax credits than the L Van, and will require a dedicated capital raise to fund production in the Charlotte factory. Start of production in Charlotte is targeted for late 2024. Igor Torgov, previously an Arrival executive, has been appointed as CEO to lead the execution of the newly approved plan, with his intimate knowledge of Arrival's business priorities, technologies and talent.

08:58 EDT Myomo Sees Q1 product revenue increasing 15%-20% YoY - "We expect first quarter 2023 product revenue to increase between 15% and 20% compared with the first quarter of 2022," added Mr. Gudonis. "Given the strength of the patient pipeline entering 2023 - now only with reliable payers- we believe full-year product revenue growth of between 20% to 30% is attainable."

08:57 EDT Charles Schwab reports February total client assets down 4% from last year - The Charles Schwab Corporation released its February Monthly Activity Report, stating: "Core net new assets brought to the company by new and existing clients totaled $41.7 billion. Net new assets excluding mutual fund clearing totaled $40.5 billion. Total client assets were $7.38 trillion as of month-end February, down 4% from February 2022 and down 1% compared to January 2023. Average margin balances were $60.6 billion in February, down 28% from February 2022 and up 1% compared to January 2023."

08:54 EDT iCAD engages bankers to explore strategic options for Therapy business line - The Company is implementing measures to align its cost base with changes in revenue from its ongoing transition from perpetual to subscription software licenses, while maintaining investments in key growth initiatives. The Company has also engaged investment bankers to explore strategic options for its Therapy business line.

08:50 EDT Clubhouse Media announces new reduction in company debt - Clubhouse Media Group announced that it has reduced its outstanding debt by approximately $95,000. Clubhouse Media's outstanding debt to noteholders remains approximately $4.3 million, following the reduction. "This is another step in the right direction" said Scott Hoey, Chief Financial Officer of Clubhouse Media. "We've made great strides in the past few months in terms of reducing our outstanding debt and strengthening our balance sheet."

08:50 EDT Miniso announces inclusion of its shares in the Stock Connects - MINISO Group announced that its ordinary shares have been included in the Shanghai-Hong Kong Stock Connect and Shenzhen-Hong Kong Stock Connect programs, the Stock Connects, effective on March 13, 2023, pursuant to the announcements made by the Shanghai Stock Exchange and the Shenzhen Stock Exchange, respectively. The Company has also been selected and included as a constituent stock of the following indexes by Hang Seng Indexes Company Limited, with effect from March 13, 2023: Hang Seng Composite Index; Hang Seng Composite MidCap Index; Hang Seng Composite LargeCap & MidCap Index; Hang Seng Composite MidCap & SmallCap Index; Hang Seng Composite Industry Index - Consumer Discretionary; and Hang Seng Stock Connect Greater Bay Area Composite Index

08:48 EDT Comerica down 17%, Zions Bancorp down 22% in pre-market trading - In pre-market trading, shares of Comerica (CMA) are down 17% at $48.70 and Zions (ZION) are down 25% at $30.29 - lowest levels since 2020 in both names. Analysis by MarketWatch.com has highlighted Comerica and Zions as top two regional banks with the highest ratios of negative AOCI - or accumulated other comprehensive income - to total equity capital that have assets of at least $10.0B as of the end of 2022. Reference Link

08:48 EDT Antelope Enterprise announces letter to shareholders from CEO Zhang - Antelope Enterprise announced the following Open Letter to the Company's shareholders from Chairman and Chief Executive Officer Weilai Zhang. "As we had reported in our previous press releases and earnings reports, China's real estate sector has experienced a significant slowdown over the past few years which was exacerbated by the impact of the Covid-19 pandemic... As a key element of this transformation, in December 2022 the Company's Board of Directors unanimously agreed to divest of its legacy ceramic tile building materials business. A special meeting of the Company's shareholders was held on February 21, 2023 and the shareholders approved the sale of this business which is expected to close pending satisfaction of customary closing conditions... As a result of our corporate transformation, we are now devoting our full resources and energies to developing our 51% owned subsidiary, Hainan Kylin Cloud Services Technology, which operates a leading social and livestreaming social ecommerce platform in China... We believe that KylinCloud has the core competencies and competitive advantages to sustain its leading market share and potentially dominate this key sales channel as a pure play in this sector... We believe that livestreaming social ecommerce is becoming China's growth engine for consumer brands companies since it leverages the content power of livestreaming broadcasts to engage customers and increase product sales... It is expected that livestreaming ecommerce will comprise an ever-increasing percentage of China's ecommerce sales in the years ahead spurred by a consumer ecosystem that includes a young demographic and their high usage rate of mobile devices. We are confident that China's livestreaming social ecommerce sector will experience high double-digit growth for many years to come...Over the past few months, we added four new members to the Company's Board who are highly experienced and knowledgeable about the digital economy, and whom we believe will contribute valuable guidance in fulfilling our strategic growth plan."

08:46 EDT Intelligent Bio Solutions selects HASTA Laboratory as drug testing specialist - Intelligent Bio Solutions announced that the Company has selected Human and Supplement Testing Australia as its preferred drug testing specialist in Australia to complete lab-based confirmation testing for its Intelligent Fingerprinting System, which analyzes sweat to screen for recent drug use.

08:46 EDT Healthcare Triangle confirms no exposure to SVB - Healthcare Triangle (HCTI) confirms that it does not hold any cash or maintain any accounts at Silicon Valley Bank (SIVB), and has no current or prior business relationship with SVB.

08:45 EDT Enochian Biosciences achieves full compliance with NASDAQ filing requirements - Enochian BioSciences announced that it has achieved full compliance with NASDAQ filing requirements. The Annual Report on Form 10-K was filed on February 27, 2023, followed by the Quarterly Reports on Forms 10-Q for the quarters ending September 30, 2022 and December 31, 2022 on March 7th and March 9th, 2023, respectively.

08:44 EDT Surgalign announces release of HOLO AI Insights for spine imaging - Surgalign Holdings announces the release of HOLO AI Insights. HOLO AI Insights enables customers, partners, and clinical researchers to take advantage of the Company's HOLO artificial intelligence portfolio through a secure, highly scalable cloud platform for automated analysis of medical images. HOLO AI, Surgalign's portfolio of AI technology, utilizes convolutional neural network technology to automate various tasks such as segmenting medical images, measuring anatomic structures, and planning pedicle screw placement. As part of Surgalign's HOLO AI portfolio, HOLO AI Insights analyzes standard protocol lumbar spine MRI images, providing quantitative measurements of 16 different anatomic structures in the spine. Currently, this image processing is being utilized for retrospective data analysis of patient specific medical information from participating sites. The insights generated have the potential for multiple applications in population health, clinical research, and in the future, patient care.

08:41 EDT Installed Building Products acquires Anchor Insulation, no terms given - Installed Building Products announced the acquisition of Anchor Insulation . Established in 1980, Anchor Insulation is headquartered in Pawtucket, Rhode Island and primarily installs residential, mechanical and industrial insulation. Anchor Insulation serves residential, commercial and industrial customers across the Northeast from branches in Rhode Island, Connecticut, and Massachusetts. "With approximately $39M of annual revenue, Anchor Insulation expands our presence to residential, commercial and industrial customers across the Northeastern United States," stated Jeff Edwards, Chairman and Chief Executive Officer. "To date in 2023, we have acquired approximately $43M of annual revenue. Acquisitions remain a key component of our growth strategy and we continue to have a robust pipeline of opportunities across multiple geographies, products, and end markets. On behalf of everyone at Installed Building Products, I want to welcome Anchor Insulation onto our team."

08:41 EDT Indaptus Therapeutics activates Emory Winship Cancer Institute as trial site - Indaptus Therapeutics announces that Atlanta, Ga.-based Emory Winship Cancer Institute has become a new clinical trial site for INDP-D101. INDP-D101 is the Company's first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors. Emory has begun screening patients. The study's objectives are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose and recommended phase 2 dose, as well as to assess Decoy20 pharmacokinetics, pharmacodynamics and clinical activity. The Phase 1 study was initiated with a single dose escalation, which is planned to be followed by an expansion with continuous weekly administration of Decoy20. The study is enrolling patients with advanced/metastatic solid tumors, who have exhausted approved treatment options. The primary endpoint of the study is incidence, relatedness and severity of adverse events and treatment-emergent adverse events and determination of the number of subjects per cohort with dose limiting toxicity-based adverse events. Secondary endpoints include the incidence of anti-drug antibodies and neutralizing antibodies pre- and post-treatment, change in Decoy20 PK parameters over time, objective response rate in subjects with measurable disease and duration of response.

08:38 EDT NewtekOne provides update on financial holding company transition, forecasts - On January 6, 2023, NewtekOne (NEWT) completed the acquisition of National Bank of New York City, withdrew its BDC election, and became a financial holding company. On January 13, 2023, Newtek Business Services Corp. changed its name to NewtekOne and NBNYC, the 59-year-old nationally chartered bank, was renamed Newtek Bank, National Association, a wholly owned subsidiary of NewtekOne. As a result, NewtekOne, a financial holding company, no longer qualifies as a regulated investment company for federal income tax purposes and will no longer qualify for accounting treatment as an investment company. Going forward, Newtek Bank, N.A. and NewtekOne's former portfolio companies and other subsidiaries will be consolidated in the Company's financial statements. As a result, NewtekOne's financial reporting metrics will change beginning with the first quarter 2023 quarterly report. Barry Sloane, Chairman, President and CEO said, "Given the volatility in capital markets and banking deposit funding, we thought it would be useful to update the market on our transition to a financial holding company. Important to note, neither NewtekOne or its subsidiaries are borrowers or depositories with Silicon Valley Bank (SIVB) or Silvergate Bank (SI). In addition, Newtek Bank, N.A., as a depository, only accepts USD currency and has zero exposure to any depositor or borrower who wants to transact in crypto currency, and does not accept or recognize it as a form of currency or barter."

08:37 EDT OverActive Media announces Toronto Ultra wins Call of Duty League championship - OverActive Media announced that its Call of Duty League franchise, Toronto Ultra, won the Major III Championship in Arlington, TX yesterday. he Toronto Ultra roster was recently refreshed, bringing up rookie Charlie "Hicksy" Hicks from his substitute position to join Jamie "Insight" Craven, Tobias "CleanX" Jonsson and Thomas "Scrap" Ernst. The win solidified Charlie "Hicksy" Hicks as the first player since 2011 to win a championship in their first Local Area Network tournament. The roster has come up through OverActive Media's player development system, all making their professional Call of Duty League debut with Toronto Ultra.

08:36 EDT Pliant: Enrollment for Phase 2a bexotegrast trial has commenced following review - Pliant Therapeutics announced that, following an independent Data Safety Monitoring Board safety review, enrollment has commenced in a Phase 2a trial of bexotegrast at 320 mg dosed once daily for at least 24 weeks and up to 48 weeks in patients with primary sclerosing cholangitis. Bexotegrast, is an oral, small molecule, dual-selective inhibitor of alphavbeta6 and alphavbeta1 integrins being developed for the treatment of PSC and idiopathic pulmonary fibrosis. Bexotegrast has been administered to over 600 study participants to date, including healthy volunteers and patients, with no drug-related severe or serious adverse events reported to date. "We are pleased to see the continued favorable safety and tolerability profile exhibited by bexotegrast, allowing us to evaluate a higher dose at a longer treatment duration in patients with PSC," said Eric Lefebvre M.D. Chief Medical Officer of Pliant Therapeutics. "We recognize the high unmet medical need in PSC, as there are no FDA approved therapies for the indication and look forward to sharing 12-week interim data from our Phase 2a trial in the third quarter."

08:35 EDT Pliant: Enrollment for Phase 2 bexotegrast has commenced following DSMB review - Pliant Therapeutics announced that, following an independent Data Safety Monitoring Board safety review, enrollment has commenced in a Phase 2a trial of bexotegrast at 320 mg dosed once daily for at least 24 weeks and up to 48 weeks in patients with primary sclerosing cholangitis. Bexotegrast, is an oral, small molecule, dual-selective inhibitor of alphavbeta6 and alphavbeta1 integrins being developed for the treatment of PSC and idiopathic pulmonary fibrosis. Bexotegrast has been administered to over 600 study participants to date, including healthy volunteers and patients, with no drug-related severe or serious adverse events reported to date. "We are pleased to see the continued favorable safety and tolerability profile exhibited by bexotegrast, allowing us to evaluate a higher dose at a longer treatment duration in patients with PSC," said Eric Lefebvre M.D. Chief Medical Officer of Pliant Therapeutics. "We recognize the high unmet medical need in PSC, as there are no FDA approved therapies for the indication and look forward to sharing 12-week interim data from our Phase 2a trial in the third quarter."

08:32 EDT BioVie pauses patient enrollment in ascites Phase 2b trial - BioVie announced that patient enrollment in the Company's Phase 2b clinical trial, evaluating BIV201 for the treatment of refractory ascites, has been paused. Encouraging data from the first 15 patients in the study is announced. Treatment with BIV201 plus standard of care resulted in a 34% reduction in ascites fluid during the 28 days after treatment initiation compared to the 28 days prior to treatment. This improvement was significantly different from those treated with SOC only who experienced a mean increase in ascites fluid of 3.1%. Patients who completed the treatment with BIV201 experienced a 53% reduction in ascites fluid, which was significantly different from those treated with SOC (p=0.007). This improvement was sustained in this group during the 3 months after treatment initiation as compared to the 3-month pre-treatment period (43% reduction, p=0.06). Overall treatment appeared to be well tolerated. There were no unexpected serious adverse events and overall safety was consistent with the patient population. Detailed results will be presented at an upcoming Scientific conference. Ascites is a common complication of advanced liver cirrhosis involving the accumulation of large volumes of fluid in the abdomen, often exceeding 5 liters, due to liver and kidney dysfunction. The FDA has never approved a drug to treat ascites, and once patients reach the refractory stage the estimated one-year survival rate is only approximately 50%1. BIV201 is a continuous infusion of terlipressin, a drug used in over 40 countries to treat related complications of liver cirrhosis that was recently approved in the US but not Japan. With the novel prefilled room temperature stable syringe used in this study, BIV201 could potentially provide a superior terlipressin drug delivery system throughout the world. The current trial evaluates the efficacy of BIV201 combined with standard-of-care, compared to SOC alone, for the treatment of refractory ascites. Terlipressin was administered with a continuous low dose infusion via a portable pump in two 28-day treatment cycles. The primary endpoints are the incidence of complications of at least Grade 2 severity, and the change in cumulative ascites in the 12-week period following randomization compared to a 12-week pre-treatment period. The BIV201 trial planned to enroll 30 patients to be treated in the home care setting. BIV20 has received Orphan Drug and Fast Track designations from the FDA for the treatment of ascites due to all etiologies except cancer. This would include, for instance, ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive seven years of market exclusivity in the US for the designated use.

08:29 EDT Paltalk confirms no relationship with Silicon Valley Bank - Paltalk has no banking or other financial relationship with Silicon Valley Bank. Paltalk does not have any assets on deposit with Silicon Valley Bank, nor does the Company maintain any other financial relationship with the bank or its affiliated entities.

08:27 EDT Aridis meets primary, secondary endpoints in Phase 2a study of AR-501 - Aridis Pharmaceuticals announced preliminary top-line results from the randomized, double blinded, placebo-controlled Phase 2a study of AR-501, which evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol in cystic fibrosis patients with confirmed Pseudomonas aeruginosa bacterial and other potential infections. The study was conducted with funding support from the Cystic Fibrosis Foundation. AR-501 is being developed as a once-per-week inhaled dosing regimen that is self-administered using a commercially available nebulizer device. Key findings: The study's primary and secondary endpoints of safety and pharmacokinetics were met; Three weekly inhaled doses of AR-501 at 6.4mg, 20mg, and 40mg dose levels were well tolerated in CF patients. No drug related serious adverse events were observed. The majority of treatment emergent adverse events were respiratory in nature and mostly mild to moderate in severity; CF patients achieved high uptake of AR-501 in the respiratory tract, as measured by sputum concentrations, at levels that were more than 50-fold higher than required for inhibition of the target bacteria P. aeruginosa; Inhaled delivery achieved more than 10-fold higher respiratory uptake of gallium than past clinical studies of intravenous gallium which resulted in lung function improvement and P. aeruginosa reduction. The study was primarily designed as a safety and PK trial in clinically stable cystic fibrosis subjects and due to the heterogeneity of concurrent medicine use in the study subjects, exploratory objectives, such as microbiological burden of P. aeruginosa and lung function, were not established in this study.

08:23 EDT Genetic Technologies announces publication of research on geneType test - Genetic Technologies announced the publication of another research paper supporting the utilisation of geneType Breast Cancer Risk Assessment Test in the peer-reviewed journal Cancer Prevention Research. Highlights: 2nd published peer reviewed paper in the last month supporting the use of geneType, on the back of the ASX release dated February 9, 2023. Utilised a prospective cohort of more than 200,000 women from the UK Biobank. geneType Breast Cancer Risk Assessment Test demonstrated improved performance compared to a gold-standard model over a 5-year period. The study showed that geneType not only put more women into an increased risk category but also demonstrated women in this category developed breast cancer at a higher incidence. The paper entitled: Validation of an abridged breast cancer risk prediction model for the general population, reports results from an extensive study undertaken by the GTG Scientific Team in collaboration with Professor John Hopper from the Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne. This study is the third paper accepted for publication in the last six months that highlights the utility of the geneType Breast Cancer Risk Assessment Test as powerful risk stratification tool available to the general population. GeneType improved discrimination and risk categorization when compared to one of the most well-known models, the Breast Cancer Risk Assessment Tool. Over a five-year period, at-risk women classified greater than or equal to3% 5-year risk by geneType had a 1.829 times increased incidence of breast cancer compared to the general population, which was higher than the 1.413 times increased incidence for women classified greater than or equal to3% by BCRAT.

08:21 EDT Acasti Pharma to delist shares on TSXV, confirms no exposure to SVB - Acasti Pharma (ACST) announced that it has applied and received approval for a voluntary delisting of its common shares from the TSX Venture Exchange, TSXV. The delisting from the TSXV will not affect the Company's listing on the NASDAQ Capital Market. The common shares will continue to trade on the NASDAQ under the symbol "ACST". The Company believes that the trading volume of its shares on the TSXV no longer justifies the expenses and administrative efforts required to maintain a dual listing. The Company also believes that delisting from the TSXV will create a central marketplace for its common shares on the NASDAQ, and ultimately benefit the long-term liquidity and shareholder value of the Company. It is anticipated that, effective as at the close of trading on March 27, 2023, Acasti's common shares will no longer be listed and posted for trading on the TSXV. The Company also confirms that neither Acasti, nor any of its subsidiaries have any exposure to Silicon Valley Bank, SVB, (SIVB) or Silvergate Bank. The Company has no deposits with those institutions, and has been financed through equity issuances in the past and not from any form of debt or other interest bearing securities

08:20 EDT Vectivbio, Asahi Kasei commence Phase 1 study of apraglutide - VectivBio Holding and Asahi Kasei Pharma announced the start of a Phase 1 study investigating the pharmacokinetics, pharmacological action, safety, and tolerability of apraglutide when a single subcutaneous dose is given to healthy Japanese adult men and women. Pharmacological actions and safety will be investigated by comparison with a placebo control. In March 2022 VectivBio entered into an exclusive licensing agreement with Asahi Kasei Pharma to develop and commercialize apraglutide, a next-generation, long-acting GLP-2 analog, for the treatment of short bowel syndrome with intestinal failure, steroid-refractory acute graft-versus-host disease and future indications in Japan. VectivBio received an upfront cash payment of approximately $30 million and is eligible for up to approximately $170 million in further development activities and milestone payments upon the achievement of certain development, regulatory and commercial milestone events. VectivBio is also eligible to receive tiered, double-digit, escalating royalties on sales of apraglutide in Japan. VectivBio is conducting the STARS Phase 3 global program studying apraglutide in patients with SBS-IF with 93 sites in 18 countries, including multiple sites in Japan. This newly initiated Phase 1 study in healthy Japanese volunteers, conducted by Asahi Kasei Pharma, is expected to be the only Japan-specific clinical study necessary to file a marketing authorization application in Japan.

08:18 EDT Mesa Labs reports 'immaterial' financial exposure to SVB - Mesa has monitored the situation at Silicon Valley Bank, whereby on March 10, 2023, the California Department of Financial Protection and Innovation closed SVB and placed it under control of the United States Federal Deposit Insurance Corporation as receiver. According to the FDIC, depositors will have access to all of their money starting Monday, March 13, 2023. Mesa has taken proactive steps to mitigate risk to the Company, which continues to believe that its existing cash and cash equivalents balance and cash flow from operations will be sufficient to meet its working capital, capital expenditures, and material cash requirements from known contractual obligations for the foreseeable future. Mesa's deposit accounts held at SVB in excess of the $250,000 FDIC-insured limits are less than $500,000. Mesa believes this is immaterial when compared to the Company's total balance of cash and cash equivalents which were $26.1 million as of December 31, 2022 and are held on deposit at multiple large financial institutions across the world. Other than the deposit accounts noted, Mesa has no material positions or relationships with SVB.

08:17 EDT Ovid Therapeutics expects cash to provide runway into 1H25 - Cash, cash equivalents and marketable securities as of December 31, 2022 totaled $129.0 million

08:14 EDT ProPhase Labs announces data presentation on BE-smart Test - ProPhase Labs announced it will be giving a data presentation at the United States and Canadian Academy of Pathology, which is being held March 11 - 16, 2023, at the Ernest N. Morial Convention Center in New Orleans, LA. The senior author of the presentation is Christopher P. Hartley, MD of the Mayo Clinic, a board-certified pathologist, and principal investigator of the Collaborative Research Agreement with the Mayo Clinic to assess the performance of the Company's BE-smart Test that detects and quantifies hallmarks of cancer development in tissue of patients diagnosed with Barrett's esophagus, a precancerous condition with high incidence in the United States. The Director of Norton Thoracic Institute, Dr. Sumeet Mittal, Dr. Catherine Hagen of the Mayo Clinic, Dr. Sheeno Thyparambil of mProbe Inc. and Dr. Joe Abdo, scientific advisor to ProPhase Labs, serve as co-authors of the study. Dr. Andrew Cannon, an anatomic and clinical pathology resident at the Mayo Clinic serves as first author and will be giving the presentation to attendees of USCAP on Tuesday, March 14th.

08:13 EDT Potbelly finalizes multi-unit development agreement, refranchising deal in NYC - Potbelly Corporation announced it has finalized a multi-unit development agreement along with its first refranchising deal in New York City. This agreement includes multi-unit development for 13 new shops over the next eight years, and the refranchise of eight shops, the ownership of which has been fully transferred. United One Group acquired the eight existing Potbelly locations in New York City, and additionally committed to developing 13 new shops over the next eight years. UOG is an experienced franchise group, led by Chief Executive Officer Paramjit Josan and Chief Development Officer Manny Singh. Combined, the UOG team has over 75 years of restaurant experience, developing and operating fast casual, quick service restaurants, and sandwich-specific brands as well as other hospitality-focused businesses. Additionally, UOG has deep experience in the Manhattan region and real estate market. As part of the Franchise Growth Acceleration Initiative announced in March 2022, Potbelly plans to reach 2,000 units with at least 85% of those being franchised shops over the next 10 years. The brand also plans to refranchise approximately 25% of its company owned shops in conjunction with Shop Development Area Agreements.

08:10 EDT AppLovin confirms Silicon Valley exposure minimal with less than $2M - AppLovin issued the following statement regarding the closure of Silicon Valley Bank by the California Department of Financial Protection and Innovation or CDFPI, and appointment of the Federal Deposit Insurance Corporation as receiver of SVB. AppLovin has over $1B in cash and cash equivalents with less than $2M at SVB as of March 10 and no SVB-related credit facilities. We expect to operate our business in the ordinary course and will continue to carefully monitor the situation.

08:10 EDT SVB Financial appoint restructuring committee to explore strategic alternatives - SVB Financial Group announced that its Board of Directors has appointed a restructuring committee consisting of five independent directors to explore strategic alternatives for the holding company and its SVB Capital and SVB Securities businesses, as well as its other assets and investments. Both of these businesses are separate divisions of SVBFG and not part of Silicon Valley Bank, which is undergoing resolution under the jurisdiction of the Federal Deposit Insurance Corporation and Federal Reserve. The members of the holding company's restructuring committee are Eric Benhamou, Tom King, Kay Matthews, Mary Miller and Kate Mitchell. In addition to exploring potential transactions for the SVB Capital and SVB Securities businesses, the committee will explore all alternatives for addressing the approximately $3B of funded debt held by the holding company, which is recourse only to SVB Financial Group and is not guaranteed by the subsidiaries. The holding company is being advised by Centerview Partners LLC, Sullivan & Cromwell LLP, and Alvarez & Marsal as financial, legal, and restructuring advisors, respectively, in conjunction with the committee's activities.

08:08 EDT Mobiv Acquisition enters merger agreement with Srivaru Holding - Mobiv Acquisition, a special purpose acquisition company with a focus on electric vehicles, announced it has entered into a definitive merger agreement whereby Mobiv will combine with SRIVARU Holding Ltd., a commercial-stage provider of premium electric motorcycles, to create a new publicly traded company. The transaction is expected to provide SRIVARU with access to additional capital and position the company to accelerate the commercial rollout-out of its electric two-wheeled vehicles in the Indian market. SRIVARU is one of the leading providers of premium electric motorcycles in India. The combined company will be known as SRIVARU Holding Ltd. and will be led by SRIVARU's current management team. The transaction is anticipated to generate gross proceeds of up to approximately US$104 million of cash, assuming no redemptions by Mobiv's public stockholders, which will be used to fund operations and growth. The pro forma implied enterprise value of the combined company is approximately $195 million. Including the vehicle sales revenue-based earn-out for SRIVARU shareholders of 25 million shares, the implied total consideration to SRIVARU shareholders will be approximately $409 million, assuming $10 per share. The earnout for vehicle sales is based on SRIVARU achieving sales revenue for vehicles and such other products as approved by the board of SRIVARU of US$39 million for the fiscal year ending March 31, 2024, $117 million for the fiscal year ending March 31, 2025, and $553 million for the fiscal year ending March 31, 2026. Mobiv's net cash proceeds, which exclude any potential common stock redemptions, will be used to fund SRIVARU's strategic plan to accelerate its go-to-market strategy, invest in new product development, and enhance its global manufacturing and distribution capabilities. The transaction has been approved by the boards of directors of both SRIVARU and Mobiv, and is expected to close in the first half of 2023, subject to the approval of Mobiv stockholders, regulatory approvals, and other customary closing conditions.

08:07 EDT Strata Skin Sciences confirms no exposure to Silicon Valley Bank - STRATA Skin Sciences (SSKN) announced it does not have exposure to Silicon Valley Bank. STRATA does not hold cash deposits or securities with Silicon Valley Bank (SIVB), and does not otherwise have a business relationship with Silicon Valley Bank.

08:07 EDT NV5 Global announces $11M in engineering, planning awards - NV5 Global has been awarded $11 million in new contracts by the New York City Department of Parks and Recreation to provide engineering design throughout the City and planning services for the Coney Island Boardwalk reconstruction. NV5 was selected for a three-year, $9 million contract to design civil and structural engineering improvements for facilities such as parks, recreation centers, piers, marinas, and waterfront structures. This contract is NV5's first engineering design agreement with the Department of Parks and Recreation and expands upon the landscape architecture, planning, and inspection services that NV5 currently provides to the agency. NV5 was also awarded a $1.5 million contract to develop a phasing plan and design guidelines for The Coney Island Boardwalk Pre-Design Study. The study is the first phase of a project to reconstruct the boardwalk to address its deteriorating condition and improve the resiliency of the boardwalk, adjacent facilities, and surrounding neighborhoods.

08:04 EDT Latch reports approximately $3.1M in various accounts with SVB - Latch is aware that the Federal Deposit Insurance Corporation has been appointed receiver of Silicon Valley Bank due to concerns regarding SVB's liquidity and the closure of SVB by the California Department of Financial Protection and Innovation. As of March 8, 2023, the Company had deposits in various accounts with SVB of approximately $3.1 million, which represents less than 2% of the Company's total cash and cash equivalents and current and non-current available-for-sale securities. The Company is also aware that the FDIC has been appointed receiver of Signature Bank. The Company does not have any deposits with Signature Bank. The U.S. Department of the Treasury, the U.S. Federal Reserve, and the FDIC issued a joint statement on March 12, 2023, announcing that "Secretary [of the Treasury Janet L. Yellen] approved actions enabling the FDIC to complete its resolution of [SVB] in a manner that fully protects all depositors" and that "[d]epositors will have access to all of their money [held in SVB bank accounts] starting Monday, March 13." Upon receipt of all or a portion of its deposits held in SVB bank accounts, the Company intends to transfer such deposits to an internationally recognized and reputable money center bank. The Company's total cash and cash equivalents and current and non-current available-for-sale securities as of March 8, 2023, was approximately $215.4 million. Of this $215.4 million, approximately $61.4 million is in a custodial account held by U.S. Bank National Association and for which SVB Asset Managemen has provided investment management services. The Company has initiated the process to appoint a different third-party advisor to perform such investment management services and, at this time, the Company does not believe it will suffer a material loss in respect of the assets held by U.S. Bank in relation to the foregoing arrangement with SVB Asset Management. Due to the recent developments involving SVB, it is possible the Company could experience delays in the transition of the investment management services performed by SVB Asset Management to a different third-party advisor.

07:59 EDT Iris Energy confirms no deposits with SVB, Signature Bank or Silvergate Capital - In respect of recent market events, in particular developments in relation to Silicon Valley Bank (SIVB), Silvergate Capital (SI) and Signature Bank (SBNY), the Company confirms it does not hold deposits or securities or maintain any accounts with any of these entities.

07:56 EDT SPDR Regional Banking ETF extends decline, down over 6% in pre-market - SPDR Regional Banking ETF KRE is down another 6.5% or $3.29 at $47.40 in pre-market trading. The ETF, which had featured SVB Financial (SIVB) as one of its top holdings, was down 16% last week as SVB was taken under receivership by the FDIC.

07:49 EDT NeoGenomics announces launch of Neo Comprehensive CGPs - NeoGenomics announced the expansion of their next-generation sequencing portfolio of products with the commercial availability of multiple tests, including Neo Comprehensive - Solid Tumor, a comprehensive genomic profile for solid tumor cancers, and Neo Comprehensive - Myeloid Disorders, a CGP for myeloid neoplasms. Neo Comprehensive - Solid Tumor is NeoGenomics' largest solid tumor, pan cancer assay available to date. This CGP detects genomic alterations that are most relevant in diagnosis, therapy selection, prognosis and clinical trials. The panel includes 517 genes by both DNA and RNA NGS, microsatellite instability, and tumor mutational burden. With this test comes an improved turnaround time and a streamlined test report format. Neo Comprehensive - Myeloid Disorders is available as an enhancement of NeoGenomics' previous Myeloid panel, making it the largest DNA and RNA NGS myeloid panel on the market with the most clinically actionable features, including single nucleotide variants, copy number variants, insertions and deletions, and fusions. In parallel with the two product launches, NeoGenomics is also introducing two software resources to complement their testing menu: NeoAccess, a test requisitioning tool which includes clinical decision support, up-front patient benefits check and prior authorization assistance abilities; and NeoSeek, a platform that allows clinicians the ability to mine their previous testing data to identify their patients who may be biomarker eligible for a new therapy or clinical trial.

07:46 EDT Applied Materials increases quarterly cash dividend 23.1% to 32c per share - Applied Materials announced that its Board of Directors has approved a 23.1-percent increase in the quarterly cash dividend from 26c to 32c per share. The dividend is payable on June 15, 2023 to shareholders of record as of May 25, 2023.

07:42 EDT DexCom has no material exposure to developments at Silicon Valley Bank - DexCom (DXCM) issued the following statement in response to speculation following the developments at Silicon Valley Bank (SIVB), including a recent CNBC article: "Dexcom does not have material exposure to the developments at Silicon Valley Bank, including with respect to the company's cash deposits. Although the company has worked successfully with SVB for many years, Dexcom does not have any exclusive banking relationship with SVB. As noted in Dexcom's recent filing on form 10-K, the company currently retains approximately $2.5B in cash, cash equivalents, and short-term marketable securities. Approximately $2.7M of this amount is held at SVB."

07:40 EDT Gracell sees cash runway to the end of 2024 - As of December 31, 2022, the Company had RMB1,458.2 million in cash and cash equivalents and short-term investments.

07:37 EDT Cryptyde in development of AI generated content platform - Cryptyde announced that development is underway for an AI generated content platform for its subsidiary, Forever 8. This platform will provide a user-friendly interface that generates unique and engaging content to be used across the company's e-commerce ecosystem, from product descriptions and FAQs to customer service responses. Leveraging advanced machine learning abilities, this cutting-edge technology will enable us to quickly and efficiently generate high-quality content for our clients. The platform's human-like responses to questions and prompts will provide Forever 8 with a competitive advantage, allowing us to create compelling marketing and support materials for clients.

07:36 EDT Enovix announces several leadership additions - Enovix announced multiple leadership additions in key functional roles to support the company's scale-up. Recent appointments include: Samira Naraghi as Vice President of Product Management. Naraghi joins Enovix in a newly established role and will report to Dr. Talluri. She is responsible for planning and driving products and strategic programs across all organizations of the company. Most recently, she served as global head of partnerships for Meta Connectivity. Milind Patil as Vice President of Global Procurement. Patil joins Enovix from semiconductor capital equipment leader Lam Research, where he most recently served as Managing Director of Global Supply Chain, Global Operations, overseeing a multi-billion-dollar global supply chain spend. At Enovix, Patil will oversee a procurement process that spans the full stack of battery production, from raw materials to capital equipment. He will report to Chief Operating Officer Ajay Marathe. Mani Balasubramanian as Vice President, Controller. Mani joins Enovix from Lumileds, where he has most recently served as Vice President of Finance for the Automotive Business Unit and Operations. At Enovix, Mani will be focused on product costing, margin analysis, and directing financial planning and budgeting. He will report to Chief Financial Officer Steffen Pietzke.

07:35 EDT Mersana Therapeutics announces clinical hold on XMT-2056 Phase 1 trial - Mersana Therapeutics announced that the Phase 1 trial of XMT-2056 has been placed on clinical hold by the U.S. Food and Drug Administration. This action follows the company's communication to FDA that Mersana was voluntarily suspending the trial due to a recent Grade 5 serious adverse event that was deemed to be related to XMT-2056. The SAE and its cause remain under investigation. XMT-2056 is Mersana's first Immunosynthen STING-agonist ADC product candidate to enter the clinic, and the SAE occurred in the second patient who had been enrolled at the initial dose level in the dose escalation portion of the Phase 1 trial in previously treated patients with HER2+ recurrent or metastatic solid tumors. During the clinical hold, no patients will be enrolled or dosed in the trial.

07:34 EDT Marimed closes on acquistion of Ermont operating assets - MariMed and Ermont announced the close of MariMed's transaction to acquire the operating assets of Ermont. The deal was previously announced on February 21, 2023. The acquisition marks the second medical dispensary for MariMed in Massachusetts, substantially completing the Company's buildout to the maximum allowable by state regulations. The transaction closed on March 9, 2023, and the dispensary began operations under the Panacea Wellness brand name the following day. The dispensary now features an expanded selection of the best cannabis products produced in the state, including those in MariMed's award-winning brand portfolio: Nature's Heritage flower and concentrates; Betty's Eddies fruit chews; Bubby's Baked soft-baked goods; Vibations: High + Energy drink mixes; and the full suite of its InHouse branded products. MariMed's branded cannabis products are distributed to virtually all the dispensaries in the Massachusetts cannabis market, which generated $1.8 billion in total cannabis sales during 2022, according to the Massachusetts Cannabis Control Commission. MariMed's acquisition includes two Host Community Agreements with the city of Quincy, one of which is to conduct adult-use cannabis sales. The Company is applying with the CCC for approval of adult sales and plans to expand the existing medical dispensary to accommodate the increased demand. Plans also include repurposing the cultivation facility and moving its pheno-hunting activities from their New Bedford cultivation and processing facility to free up space for much needed additional capacity of their award-winning Nature's Heritage flower. MariMed is partnering with Little Dog for the delivery of medical and adult-use cannabis where permitted. The closing of this transaction is the result of a successful restructuring conducted by court-appointed receiver Opus Consulting Partners LLC. Opus Consulting and MariMed negotiated the transaction with court approval, and the acquisition was approved by the CCC on March 9, 2023. This is the first cannabis receivership in New England and a first-of-its-kind transaction. Receivership is a court-appointed pathway used by struggling businesses and creditors as an alternative to bankruptcy. Because cannabis remains a Schedule I substance under the US Controlled Substances Act of 1970, most businesses engaged in its cultivation, manufacturing, sale, and distribution do not have access to federal bankruptcy protection.

07:30 EDT Abivax says does not hold any cash at SVB or any U.S. financial institution - Abivax is aware that Silicon Valley Bank was closed on March 10, 2023, by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. The Company does not hold any cash or otherwise have any deposits at SVB or at any other U.S. financial institution, and it does not have any banking relationship with SVB. The Company has no exposure to any liquidity concern at SVB or any other U.S. financial institution.

07:28 EDT uniQure announces inducement grants under Nasdaq listing rule - uniQure announced that the Company granted equity awards to 31 employees as a material inducement to commencing their employment. The equity awards were approved by the Company's board of directors on February 23, 2023 in accordance with Nasdaq Listing Rule 5635(c)(4). In the aggregate, the employees received 63,300 restricted share units and options to purchase 57,500 ordinary shares of the Company. Each option has an exercise price of $20.06 per share, the closing price per ordinary share as reported by Nasdaq on February 23, 2023. Each option has a ten-year term and will vest over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and an additional 6.25% of the shares vesting in approximately equal quarterly installments over the twelve successive quarters thereafter. The RSUs will vest over three years, with one-third of the RSUs vesting annually on each successive anniversary of the Grant Date. The vesting of each option and RSU is subject to the employee's continued service with the Company through the applicable vesting dates.

07:26 EDT Wesdome announces Mineral Resource, Reserve updates for Eagle River, Kiena - Wesdome Gold Mines announces updated Mineral Resource and Mineral Reserve updates at the Company's 100% owned Kiena Mine Complex in Val d'Or, Quebec and at the Eagle River Mine near Wawa, Ontario. High Grade Mineral Reserve Base - At December 31, 2022, Wesdome's combined proven and probable mineral reserves totalled 1.0 million ounces; combined measured and indicated mineral resources were 350 thousand ounces; and combined inferred mineral resources were 1.1 million ounces. Reserves and Resource estimates at both sites reflect higher cut-off grades, reduced exploration budget in H2, a higher allocation towards definition and infill drilling, as well as a more stringent and robust approach to reconciliation, 3D modeling and resource classification. Upgrading Near-mine Discoveries A Focus - In 2023, the Company has budgeted 137,000 metres of drilling, with a primary focus on the expansion of mineral reserves and mineral resources and delineating the new discoveries made in 2022. At Kiena, the Company is following up on multiple initial discoveries made last year, including the south limb of the A Zone and several adjacent hanging wall zones which remain outside of mineral reserves. An exploration ramp is specifically budgeted to follow-up and expand on the near-surface Presqu'ile Zone. To the west of Eagle River the Company believes there is potential for the delineation of a parallel Falcon structure and further to the East down dip extension of the high grade 300 Zone that could meaningfully enhance future operational flexibility of the asset. With an existing large resource base, efforts in 2023 will focus on converting a portion of these resources to reserves. Additionally, we have a number of recently discovered zones and exploration targets at both projects. Kiena Ramp Development Tracking Well - Since year-end, ramp development has continued to track slightly ahead of budget, with completion of the ramp to the 129 m-level scheduled by year end. Completion of this ramp segment will provide access to the high grade Kiena Deep A Zone, which is associated with areas with the highest ounces per vertical metre located within the zone.

07:25 EDT Graphite One announces results for 2022 drilling program - Graphite One announces the results of the 2022 drilling program and updated resource estimate, which shows an increase of 15.5% in Measured and Indicated tonnage with a corresponding increase of 13.1% in contained tonnes of graphite. The Measured and Indicated Resources now stand at 37.6 M tonnes at 5.14% graphite, with an Inferred Resource of 243.7 M tonnes at 5.07% graphite. "We've been very consistent about the potential we see in Graphite Creek," said Anthony Huston, President and CEO of Graphite One. "The recognition by USGS coupled with this increase in our Measured and Indicated Resources and the fact that we have explored only 26% of our graphite anomaly underscores that Graphite Creek is truly a generational resource."

07:23 EDT Genius Group to hold EGM on April 28 for Entreprenuer Resorts spinoff - Genius Group will hold an extraordinary general meeting of shareholders on April 28, 2023, at 8:00 a.m. ET. The proposal to be submitted for shareholders' approval at the EGM is to consider and vote on the resolutions for the spinoff of its subsidiary Entrepreneur Resorts and modifications to the Company's Constitution. ERL is a public listed company on the Seychelles MERJ Stock Exchange with a share price of $2.75 and market cap of $37 million, with 97% of outstanding shares owned by Genius Group. The company was acquired in June 2020 in an all-share swap, with shareholders in ERL receiving shares in Genius Group. ERL operates a Bali resort, South Africa safari and co-working cafes in Bali and Singapore. The board of directors believes the spinoff will be of benefit to shareholders, as it will streamline and rationalize the group's operations into Genius Group Ltd with its Edtech focus, and Entrepreneur Resorts Ltd, with its hospitality focus, enabling the management teams of both companies to grow their respective business models most effectively. If approved by shareholders and by court order, the spinoff will result, after NYSE and SEC approval, in all shareholders of Genius Group receiving an equal percentage of shares in ERL. Details related to the proposal and the EGM meeting will be available in the coming weeks.

07:21 EDT Hookipa Pharma appoints Terry Coelho to board of directors - HOOKIPA Pharma announced that Terry Coelho will join its Board of Directors, Audit Committee and Compensation Committee, effective April 3, 2023. She most recently served as Executive Vice President, Chief Financial Officer and Chief Business Development Officer for CinCor Pharma, Inc, through November 2022.

07:20 EDT Ritchie Bros. sells 5,100+ items for $52M+ in Rocky Mountain Regional Event - Ritchie Bros. sold 5,100+ items from three locations in its Rocky Mountain Regional Event, generating $52M+ in gross transaction value. The March 8 - 9, 2023 online and onsite auction attracted more than 12,300 bidders from 45+ countries, with buyers from the United States purchasing 92% of the equipment. The remaining 8% was purchased by international buyers from as far away as Australia, Poland, and Egypt. "We had a good crowd and aggressive bidding both onsite and online, helping drive great returns for our consignors," said Chad Apland, Regional Sales Manager, Ritchie Bros. "We sold equipment for 550+ owners from yards in Colorado, Utah, and North Dakota to buyers across the country and around the world. Thank you to all our customers for continuing to put your trust in Ritchie Bros."

07:17 EDT Asure Software says no deposit accounts with SVB or Signature Bank - Asure Software (ASUR) announced that they do not have any deposit accounts, including client funds, with either Silicon Valley Bank (SIVB) or Signature Bank (SBNY).

07:16 EDT ResMed announces results of 2023 Global Sleep Survey - ResMed announced the results from its 2023 Global Sleep Survey in conjunction with National Sleep Awareness Week and World Sleep Day to raise awareness for the importance of sleep as a key component of physical and mental health. The survey found that despite 64% of respondents saying they are satisfied with the quantity of their sleep, more than 80% report experiencing symptoms of disruption related to their sleep quality, with consumers most commonly reporting mood changes, such as depression or irritability, waking up with a dry mouth or sore throat, difficulty concentrating during the day, and excessive daytime sleepiness. The 2023 Global Sleep Survey asked more than 20,000 respondents from 12 countries during January 2023 about the quantity and quality of their sleep, bedtime routines, and sleep habits and found differences in respondents' quantity and quality of sleep based on location, gender, and age: Respondents from India, Mexico, and China are most satisfied with their quantity of sleep, while those in Australia, Japan, and the UK are the least satisfied with the quantity of their sleep. 8 in 10 respondents reported one or more symptoms of sleep disruption related to sleep quality; Mexico, France, and South Korea had the highest rates of reported symptoms, while Japan had the lowest. 60% of women report being satisfied with their quantity of sleep, compared to 68% of men and 65% of nonbinary respondents. Women and nonbinary respondents were more likely to say they have at least one symptom of poor sleep compared to men; 52% of women report regularly waking up with a negative feeling in the morning, with 26% saying they're still tired. Conversely, 58% of men report they are more likely to wake up feeling positive. 43% of Gen Xers and Boomers and 49% of the Silent Generation report that they aren't satisfied with the quality of their sleep, compared to only 37% of Millennials and 31% of Gen Zers. Despite a majority of survey respondents reporting they wake up with symptoms of poor sleep quality - one-third of respondents have not been tested for sleep apnea or sought medical help for other sleep conditions because they do not believe they have sleep-related medical conditions. Additionally, 49% of respondents said their doctor has never asked them proactively about their sleep quality.

07:14 EDT Cleveland-Cliffs raises price for hot rolled steel to $1,200 per net ton - Cleveland-Cliffs announced that it is increasing current spot market base prices for all carbon hot rolled, cold rolled and coated steel products by a minimum of $100 per net ton, effective immediately with all new orders. Cliffs' minimum base price for hot rolled steel is now $1,200 per net ton.

07:12 EDT Autolus Therapeutics reports no business relationship with Silicon Valley Bank - Autolus Therapeutics (AUTL), following recent events with Silicon Valley Bank (SIVB), announced that the company has no business relationships with Silicon Valley Bank past or present.

07:11 EDT BioRestorative Therapies to seek FDA approval to expand BRTX-100 application - BioRestorative Therapies announced that it has entered into an agreement with the Bruder Consulting & Venture Group. BCVG has been engaged to assist the Company in seeking FDA approval of the expansion of the clinical application of BRTX-100. BRTX-100 is the Company's lead clinical candidate, a novel cell-based therapeutic engineered to target areas of the body that have little blood flow. BRTX-100 is currently being evaluated in connection with a Phase 2 clinical trial in chronic lumbar disc disease. The trial is prospective, randomized, double-blinded and controlled. The trial will evaluate the safety and preliminary efficacy of a single dose of BRTX-100, including a specific release criteria of 40 million cells intradiscally injected into the nucleus of the lumbar disc. A total of up to 99 eligible patients will be randomized at up to 15 clinical sites in the United States to receive either the investigational drug (BRTX-100) or control in a 2:1 fashion.

07:10 EDT Tecnoglass raises quarterly dividend 20% to 9c per share - Tecnoglass announced that its Board of Directors has approved a 20% increase in the quarterly dividend on its ordinary shares, to $0.09 per share from $0.075 per share. At the new rate, the dividend on an annualized basis will be $0.36 per share compared to the previous rate of $0.30 per share. The Company's next quarterly dividend of $0.09 per share will be payable on April 28, 2023 to shareholders of record at the close of business on March 31, 2023.

07:10 EDT Clene expects cash to fund operations into 3Q23 - Clene's cash, cash equivalents and marketable securities totaled $23.3 million as of December 31, 2022, compared to $50.3 million as of December 31, 2021. Clene expects that its resources as of December 31, 2022, will be sufficient to fund its operations into the third quarter of 2023.

07:08 EDT Agnico Eagle CFO David Smith to retire, Jamie Porter to succeed - Agnico Eagle (AEM) announced certain senior management changes and that it will release its first quarter 2023 results on Thursday, April 27, 2023, after normal trading hours. After more than 17 years with Agnico Eagle, David Smith, most recently the executive VP, finance and CFO, has made the decision to retire as of April 28. With Smith's retirement, the company is pleased to announce that Jamie Porter will be joining Agnico Eagle effective as of May 1 in the position of executive VP, finance and CFO. Porter has over 20 years of progressive experience in the mining industry. Most recently, Jamie was the CFO of Alamos Gold (AGI).

07:07 EDT Provention Bio cancels Q4, FY22 earnings release, conference call - Provention Bio (PRVB) announced it has cancelled the release of its fourth quarter and full year financial results for the period ended December 31, 2022 due to the announcement earlier today that Provention has entered into a definitive agreement to be acquired by Sanofi (SNY), Provention's U.S. TZIELD co-promotion partner, subject to customary regulatory and other closing conditions. In addition, Provention will no longer hold its fourth quarter and full year results conference call that had been scheduled for 8:00 am E.T. Thursday, March 16, 2023. However, Provention will file its annual report on Form 10-K in compliance with the applicable Securities Exchange Commission deadline of March 31, 2023..

07:07 EDT Nexstar in multi-tear deal with Youtube TV for launch of 59 stations - Nexstar Media Group (NXST) announced that it has reached a comprehensive multi-year distribution agreement with YouTube TV (GOOG,GOOGL) to launch 59 stations on its platform, including its 29 CW-affiliated television stations, its 26 MyNetworkTV affiliates, and its four independent stations in Chicago, Washington, D.C., Oklahoma City, and Baton Rouge. The agreement also renews and extends YouTube TV's carriage of America's fastest-growing cable news network, NewsNation, which is home to such shows as "Cuomo," "Dan Abrams Live," and "Banfield." In addition, Nexstar extended carriage of all of the Company's CBS-affiliated stations on YouTube TV. Financial terms of the agreement were not released. "These agreements with YouTube TV underscore the importance of Nexstar's national and local content on its platform," said Tom Carter, Nexstar's Chief Operating Officer. "Not only will Nexstar's 40 CBS-affiliated stations continue being carried on YouTube TV, but for the first time Nexstar's 59 CW, MyNetworkTV, and independent stations will be carried on the platform, bringing Nexstar's CBS, The CW Network, and MyNetworkTV content, as well as local news, weather, sports, and other proprietary and syndicated content to YouTube TV subscribers in local markets across the country. We are also excited to be extending NewsNation's partnership with YouTube TV at a time when the network is about to expand its weekday news programming to 24-hours a day with the launch of 'Elizabeth Vargas Reports' and 'The Hill.'"

07:01 EDT Protalix announces no SVB Financial exposure - Protalix (PLX) announced that it does not hold cash deposits or securities at either Silicon Valley Bank (SIVB) or Signature Bank, nor does it have any credit facility or other financial relationship with either institution. The company maintains a majority of its cash and short-term bank deposits in money center banks in the United States with the remainder deposited in a large financial institution in Israel. The company does not expect the closure of Silicon Valley Bank or Signature Bank to have any impact on its operations. The company intends to monitor the situation and any potential impact it may have on the company's partners, suppliers or other relevant parties.

06:58 EDT Alamos Gold appoints Greg Fisher as CFO - Alamos Gold announced that Greg Fisher, Senior Vice President of Finance has been promoted to CFO effective May 1, 2023. Greg will succeed Jamie Porter who will be leaving Alamos to pursue another opportunity in the mining industry. Jamie will continue in his current capacity and help support the transition until April 28, 2023. Fisher has more than 20 years of progressive experience in the mining sector, including 13 years at Alamos Gold. Greg joined Alamos in 2010 and was appointed Vice President of Finance in 2011 and Senior Vice President of Finance in 2021.

06:51 EDT TRISO-X completes fuel test to power nuclear thermal propulsion in space - TRISO-X announced the test of its coated particle fuel for nuclear thermal propulsion applications, marking a major step toward a one-of-a-kind, nuclear-powered rocket. TRISO-X was tapped to develop key fuel fabrication processes as part of a team led by General Atomics Electromagnetic System for the first phase of the Defense Advanced Research Projects Agency's Demonstration Rocket for Agile Cislunar Operations program, which concludes this month

06:45 EDT Pfizer to acquire Seagen for $229 per share in cash

06:42 EDT New Found Gold announces results from diamond drill hole at Iceberg - New Found Gold announced the results from one diamond drill hole that was completed as part of a follow-up drill program at the new Iceberg discovery, a high-grade zone located 300m northeast of Keats Main along the highly prospective Appleton Fault Zone. New Found's 100%-owned Queensway project comprises a 1,662km2 area, accessible via the Trans-Canada Highway, 15km west of Gander, Newfoundland and Labrador. 49.7 g/t Au over 29.85m and 14.6 g/t Au over 3.80m in NFGC-23-1120 is a 25m step-down from the fence of three Iceberg discovery holes released on March 1, 2023, which outlined a new, at-surface zone traced over 50m in strike length, with the highlight interval of 72.2 g/t Au over 9.65m in NFGC-23-1100. Starting at just 35m from surface NFGC-23-1120 exhibits a nearly continuous 40m drilled mineralized interval. High-grade gold mineralization is well distributed throughout the intercept with 19 samples registering over 10 g/t Au and 9 samples grading above 50 g/t Au. Characteristics of mineralization remain consistent with those seen at Keats Main, further supporting the interpretation that Iceberg is hosted by the Keats-Baseline Fault Zone and is likely the eastern extension of Keats Main that has been displaced by faulting.

06:40 EDT Ault Alliance terminates at-the-market equity offering program - Ault Alliance has terminated its "at-the-market" equity offering program relating to sales of common stock with Ascendiant Capital Markets, LLC, as sales agent. The Company elected to terminate the ATM Facility to limit uncertainty and unfavorable dilution for its stockholders. Although the Company initiated the 5-day termination process of the ATM Facility with the Agent, with the official termination to take effect on March 17, 2023, the Company will make no further sales of shares of its common stock under the ATM Facility. Upon termination, the Company will have no further obligations related to the ATM Facility. Upon the announcement of the initiation of the ATM Facility's termination process, the Company had sold 317.9 million shares of common stock and raised approximately $176.6 million in gross proceeds, or approximately $0.56 per share.

06:35 EDT Hut 8 Mining provides update on USBTC combination - Hut 8 Mining announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 with respect to the company's proposed business combination pursuant to which Hut 8 and U.S. Data Mining Group, Inc. dba US Bitcoin Corp., or USBTC, will combine in an all-stock merger of equals. The expiration of the waiting period under the HSR Act satisfies one of the conditions to the closing of the transaction. Completion of the transaction remains subject to the remaining regulatory approvals, shareholder approval, court approval, and other customary closing conditions of the transaction.

06:33 EDT Cryoport confirms no exposure to SVB Financial - Cryoport (CYRX) confirmed that the company does not have any exposure or business relationship with Silicon Valley Bank (SIVB). Cryoport does not hold any deposits or securities or maintain any accounts at Silicon Valley Bank or with SVB Securities nor does the Company have a lending or other financial relationship with Silicon Valley Bank or its affiliated entities.

06:31 EDT CNH Industrial to acquire Augmenta at enterprise value of $110M - CNH Industrial has purchased Augmenta to accelerate the growth of their innovative Sense & Act technology. Augmenta was a previous CNH Industrial Ventures investment and a strategic partner for CNH Industrial. Sense & Act tasks are based on sensor-detected data during the spraying process, wherein protection solutions are applied to crops both before and after harvest. This technology gives machines selective spraying capabilities which precisely directs and regulates spray volume. Augmenta's work in this area includes the development of a multispectral camera and software that monitors a machine's operating environment and acts directly via the machine. This increases yield for our customers, boosts sustainability by eliminating unnecessary chemical and fertilizer usage, and most importantly reduces application time, effort and input costs. Savings in herbicide, fungicide, plant growth regulators and fertilizer represent the largest value pool for this technology. Augmenta will operate within the Raven brand, as a subset of our precision technology portfolio. It will maintain its existing employees and offices in Greece and the USA. CNH Industrial will acquire Augmenta Holding SAS at an enterprise value of $110 million, subject to customary adjustments. CNH Industrial held an existing 10.5% minority stake in the business prior to the transaction announced today, which will be funded with available cash on hand. Closing is expected to occur in the first quarter of 2023, subject to the satisfactory completion of customary closing conditions and receipt of regulatory approvals.

06:25 EDT TRX Gold reports preliminary Q2 production of 5,636 ounces of gold - TRX Gold announced preliminary Q2 2023 production of 5,636 ounces of gold, a new record for the Company and in line with previous production guidance of approximately 1,600 - 2,000 ounces of gold per month, as well as preliminary Q2 2023 sales of 5,504 ounces of gold. The average market price for gold in Q2 2023 was approximately $1,853 per ounce. Preliminary Q2 2023 gold production was higher than Q1 2023 reflecting the first full quarter of the 1,000+ tonne per day processing plant operating at full design capacity following commercial production declaration in November 2022. TRX Gold will provide additional discussion and analysis regarding its second quarter 2023 production and sales when the Company reports its quarterly results in early April 2023.

06:19 EDT Organigram receives Health Canada notification on Jolts lozenge products - Organigram Holdings received notification from Health Canada that Health Canada has determined that certain Jolts lozenge products in their 100 mg THC per package format have been improperly classified as an "extract" rather than an "edible" under the Cannabis Regulations. The Company launched the Products in August 2021 following significant research, development and regulatory work. The Company remains of the view that the patent pending Products are properly classified as cannabis extracts and compliant with the Cannabis Regulations, and is assessing its options with its legal advisors. At present, the Company has paused production of the Products in the current packaging format, pending resolution of the matter. According to Health Canada's notification, the Company can continue to sell and distribute inventory of the Products until May 31, 2023.

06:16 EDT Skillz revises Q4, 2022 earnings call date - Skillz announced that it will be reporting fourth quarter and full year 2022 financial results at 4:30 PM ET on Thursday, March 30, 2023 versus the previously announced date of 4:30 PM ET on March 14, 2023.

06:11 EDT Lantern Pharma says no exposure to SVB, Signature Bank or Silvergate Capital - Lantern Pharma (LTRN) announced that neither Lantern Pharma Inc. nor any of its subsidiaries had any exposure to Silicon Valley Bank (SIVB), Silvergate Bank (SI), or Signature Bank (SBNY). Lantern's cash, cash equivalents, and marketable securities are managed across top-tier financial institutions and with a multiple-tiered account approach. Lantern's cash, cash equivalents, and marketable securities are sufficient to continue development and current operations into 2025.

06:08 EDT Hercules Capital redoubles efforts in credit monitoring, management - The company said, "As of our most recent monthly reporting, 100% of our debt portfolio companies are current on contractual payments of principal and interest. As we work to support our portfolio companies and the venture and growth-stage market generally, we continue to focus on the continuity of our operations, portfolio and business risk management. We have redoubled our efforts in credit monitoring and management to increase our flow of information to gain insight into the economic impact this situation will have on the greater venture market and macroeconomy. Our success has always been predicated on our disciplined approach to credit underwriting and monitoring. We continue to believe in determined and consistent communications with each and every one of our portfolio companies and helping them navigate through both good and difficult times. In the coming weeks, we will continue to focus on what has made Hercules the largest and leading venture lending platform in the industry while delivering strong, sustainable long-term stockholder returns."

06:07 EDT Hercules Capital maintaining close communications with portfolio companies - The company said, "Since inception and throughout the course of our 18-year history, our belief has been that portfolio diversification and risk management is essential to achieving long-term, sustainable success in the venture and growth-stage lending space. We primarily focus on pre-IPO and M&A, innovative high-growth venture capital-backed companies at their expansion and established stages in a broadly diversified variety of technology, life sciences and sustainable and renewable technology industries. We are generally the only lender and 79.7% of our debt instruments are "true" first-lien senior secured. We do not have any direct exposure to oil and gas, metals and mining, CLOs, CMBS or RMBS, crypto or cannabis. Our debt instruments generally have short-term amortizing maturities of 36 to 48 months. At the end of 2022, our debt investment portfolio was comprised of $2.8 billion of investments, at fair value, and was split nearly evenly in exposure between technology and life sciences companies across 12 different industry sectors. Our top 5 and top 10 debt investments comprised 17.8% and 30.2% of our total debt portfolio at fair value. As the current situation continues to evolve, we are maintaining close communications with our portfolio companies to proactively assess and manage potential risks across our debt investment portfolio."

06:04 EDT Hercules Capital sees ample liquidity to support near-term requirements - The company said, "Hercules ended 2022 with over $3.6 billion of assets under management1 - an increase of 29.3% year-over-year - and strong liquidity of over $606 million. Inclusive of the Adviser Funds managed by Hercules Adviser LLC, our wholly-owned subsidiary, Hercules had approximately $1.0 billion of available liquidity to fund new investments and support existing portfolio companies as of year-end. Earlier this year, we signed a new letter of credit agreement with SMBC, which provides for a letter of credit facility of up to $100 million, and amended and extended our MUFG-led credit facility. Year-to-date through March 3, 2023, the Company sold approximately 4.2 million shares of common stock under the equity ATM program for total net proceeds of approximately $59.8 million which is highly accretive to NAV. We believe we have ample liquidity to support our near-term capital requirements. As the venture capital industry continues to assess the impact of the SVB receivership, we will continue to evaluate our overall liquidity position and take proactive steps to maintain the appropriate liquidity position based upon the then current circumstances."

05:54 EDT Sanofi acquires Provention Bio for $25 per share or $2.9B - Sanofi (SNY) and Provention Bio (PRVB) have entered into an agreement under which Sanofi has agreed to acquire Provention Bio for $25.00 per share in cash, representing an equity value of approximately $2.9B. Sanofi will commence a cash tender offer to acquire all outstanding shares of Provention. If the tender offer is successfully completed, then following the successful completion of the tender offer, a wholly owned subsidiary of Sanofi will merge with and into Provention Bio. Subject to the satisfaction or waiver of customary closing conditions, Sanofi currently expects to complete the acquisition in Q2 of 2023. "The transaction adds an innovative, fully owned, first-in-class therapy in type 1 diabetes to Sanofi's core asset portfolio in General Medicines and further drives its strategic shift toward products with a differentiated profile. TZIELD was approved in the U.S. last year as the first and only therapy to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients aged 8 years and older with Stage 2 T1D," Sanofi said in a statement.

05:26 EDT Ritchie Bros. former chairman, president speak out against merger with IAA - David Ritchie, co-founder, former chairman and director; and C Russell Cmolik, former president and director of Ritchie Bros. (RBA), released a letter to shareholders of Ritchie Bros., in connection with the proposed merger with IAA, Inc. (IAA): "As fellow shareholders of Ritchie Bros. we write to you with deep concern for the great Company we began building over 60 years ago. We have reviewed closely Luxor's analysis opposing the IAA transaction and believe that it is bang on, and that the impending merger with IAA risks negatively impacting the culture of the Company and with it, its proud legacy. Ritchie Bros. is a great business with tremendous customer support, and we believe there is no need to dilute its business in this manner. We care passionately about the Company and its ability to continue to flourish, and to be successful. Ritchie Bros. has always been exceptionally employee and customer-focused. Indeed, it has been the very culture of the Company to take the very best care of our employees and customers, first and foremost. We know customers are concerned and uneasy about this proposed merger, and what the ramifications may be to them. What a shame it would be to see this proud legacy wither to the detriment of the many valued hard-working and dedicated employees, and other stakeholders; and ultimately the value to the shareholders (many of whom are the very same employees and customers we spoke of above). In order to not interfere with the ongoing operations of the Company, we have purposely not discussed these issues with the employees of Ritchie Bros., nor relied on them for these conversations. Just a few days ago Ritchie Bros. celebrated its 25th anniversary as a public company, and should be celebrating future milestones as it continues to develop and grow its traditional core business. We believe that this is where the Company's focus should remain, not integrating a completely different business. You may ask, after all this time, why have we decided to speak up now? Frankly, after seeing several shareholders announce their opposition to the merger with IAA, and the incredible momentum provided by the recommendations of the important proxy advisors ISS and Glass Lewis to vote against the deal, we believed either the board of directors of Ritchie Bros. would seek to terminate the transaction, or shareholders would simply vote down the deal. Instead, we were alarmed to read in the press on March 10th that the merger with IAA may be approved by a small margin of shareholders. The negative reaction of the stock price to that news, consistent with the market reaction to the deal announcement on November 7, 2022 and various pronouncements since then, tells us many shareholders share our concerns. As discussed in much of the public analysis from Luxor challenging this deal, we believe the proposed merger with IAA will require an immense amount of management's time to turnaround IAA's declining business at a time when Ritchie Bros. should be re-doubling its efforts to serve its customers, employees and other key stakeholders - and grow its incredible core business. We are concerned that losing the trust and confidence of our customers, both large and small, will be detrimental to our business. We are also concerned about what the long-term prospects of the auto salvage business may be in this rapidly changing world."

05:18 EDT DBV Technologies informs investors of no exposure to SVB Financial - DBV Technologies (DBVT) informed its investors that it does not hold cash deposits or securities at Silicon Valley Bank (SIVB).

05:14 EDT MDxHealth confirms no exposure to SVB Financial, Silvergate Capital - MDxHealth (MDXH) confirmed that neither MDxHealth SA, nor any of its subsidiaries, have any exposure to Silicon Valley Bank (SIVB) or Silvergate Bank (SI).

05:04 EDT Sportradar wins bid for ATP data, betting streaming rights - Sportradar, a subsidiary of Sportradar Group, has been selected as the successful bidder for the global ATP data and betting streaming rights starting 2024. It follows an extensive RFP process led by Tennis Data Innovations, or TDI. The RFP process was initiated by TDI in January and saw five bidders submit detailed proposals across multiple rounds, for a six-year rights cycle beginning in 2024. The process took to market rights that have grown significantly in value over more than a decade. The process followed the setup in 2020 of TDI as a specialist joint venture vehicle of ATP and ATP Media to oversee innovation, development, and commercial management of all data and betting streaming products for the ATP Tour and ATP Challenger Tour.

05:01 EDT East West Bancorp provides financial update - East West Bancorp has provided the following unaudited financial update. "In light of recent industry events and market volatility, we reiterate that East West Bank's business model is diversified, our balance sheet is managed conservatively, and our liquidity is strong. Our industry-leading profitability and our high-quality earnings have resulted in very strong capital levels, which form a firm foundation for our bank," stated Dominic Ng, chairman and CEO of East West.